EP4194457A1 - Compound for targeting and degrading protein, and preparation method therefor and use thereof - Google Patents
Compound for targeting and degrading protein, and preparation method therefor and use thereof Download PDFInfo
- Publication number
- EP4194457A1 EP4194457A1 EP21852332.2A EP21852332A EP4194457A1 EP 4194457 A1 EP4194457 A1 EP 4194457A1 EP 21852332 A EP21852332 A EP 21852332A EP 4194457 A1 EP4194457 A1 EP 4194457A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- alkyl
- cycloalkyl
- optionally substituted
- membered
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 45
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 230000008685 targeting Effects 0.000 title abstract description 5
- 230000000593 degrading effect Effects 0.000 title abstract description 3
- 108090000623 proteins and genes Proteins 0.000 title description 12
- 102000004169 proteins and genes Human genes 0.000 title description 11
- 238000001814 protein method Methods 0.000 title 1
- 101000977771 Homo sapiens Interleukin-1 receptor-associated kinase 4 Proteins 0.000 claims abstract description 23
- 102100023533 Interleukin-1 receptor-associated kinase 4 Human genes 0.000 claims abstract description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 17
- 201000010099 disease Diseases 0.000 claims abstract description 15
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 11
- 108010072621 Interleukin-1 Receptor-Associated Kinases Proteins 0.000 claims abstract description 8
- 102000006940 Interleukin-1 Receptor-Associated Kinases Human genes 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 8
- 230000001404 mediated effect Effects 0.000 claims abstract description 7
- 230000015556 catabolic process Effects 0.000 claims abstract description 6
- 229940079593 drug Drugs 0.000 claims abstract description 6
- 201000011510 cancer Diseases 0.000 claims abstract description 5
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 381
- 150000002367 halogens Chemical class 0.000 claims description 379
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 379
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 329
- 125000000217 alkyl group Chemical group 0.000 claims description 309
- 125000001072 heteroaryl group Chemical group 0.000 claims description 222
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 216
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 209
- 229910052760 oxygen Inorganic materials 0.000 claims description 209
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 207
- 229910052739 hydrogen Inorganic materials 0.000 claims description 205
- 239000001257 hydrogen Substances 0.000 claims description 202
- 125000003118 aryl group Chemical group 0.000 claims description 201
- 125000005842 heteroatom Chemical group 0.000 claims description 198
- 229910052717 sulfur Inorganic materials 0.000 claims description 198
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 184
- 229910052805 deuterium Inorganic materials 0.000 claims description 184
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 143
- -1 small molecule compound Chemical class 0.000 claims description 143
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 132
- 125000001424 substituent group Chemical group 0.000 claims description 105
- 125000004043 oxo group Chemical group O=* 0.000 claims description 99
- 150000003839 salts Chemical class 0.000 claims description 99
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 94
- 229910020008 S(O) Inorganic materials 0.000 claims description 83
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 80
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 75
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 75
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 59
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 59
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 52
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 50
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 50
- 239000012453 solvate Substances 0.000 claims description 44
- 239000000651 prodrug Substances 0.000 claims description 40
- 229940002612 prodrug Drugs 0.000 claims description 40
- 125000004429 atom Chemical group 0.000 claims description 39
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 37
- JYRTWGCWUBURGU-MSSRUXLCSA-N Cl.Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](N)C(C)(C)C)cc1 Chemical compound Cl.Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](N)C(C)(C)C)cc1 JYRTWGCWUBURGU-MSSRUXLCSA-N 0.000 claims description 35
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 34
- 229910052731 fluorine Inorganic materials 0.000 claims description 29
- 229910052801 chlorine Inorganic materials 0.000 claims description 27
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 26
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 25
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 18
- 125000004076 pyridyl group Chemical group 0.000 claims description 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 13
- 125000006584 (C3-C10) heterocycloalkyl group Chemical group 0.000 claims description 12
- 208000002193 Pain Diseases 0.000 claims description 12
- 125000003386 piperidinyl group Chemical group 0.000 claims description 12
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 11
- 150000003384 small molecules Chemical class 0.000 claims description 11
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 10
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 9
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 claims description 8
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 claims description 8
- 230000001684 chronic effect Effects 0.000 claims description 7
- 125000004193 piperazinyl group Chemical group 0.000 claims description 7
- 125000006707 (C3-C12) heterocycloalkyl group Chemical group 0.000 claims description 6
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims description 6
- 206010061218 Inflammation Diseases 0.000 claims description 6
- 230000004054 inflammatory process Effects 0.000 claims description 6
- 201000009273 Endometriosis Diseases 0.000 claims description 5
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 5
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 4
- 206010020751 Hypersensitivity Diseases 0.000 claims description 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 4
- 239000003446 ligand Substances 0.000 claims description 4
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 3
- 206010013774 Dry eye Diseases 0.000 claims description 3
- 201000005569 Gout Diseases 0.000 claims description 3
- 208000009525 Myocarditis Diseases 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 208000026594 alcoholic fatty liver disease Diseases 0.000 claims description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 3
- 208000006454 hepatitis Diseases 0.000 claims description 3
- 231100000283 hepatitis Toxicity 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 208000005615 Interstitial Cystitis Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 206010034277 Pemphigoid Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 206010047642 Vitiligo Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 230000007815 allergy Effects 0.000 claims description 2
- 208000004631 alopecia areata Diseases 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 208000000594 bullous pemphigoid Diseases 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 2
- 208000030533 eye disease Diseases 0.000 claims description 2
- 208000010706 fatty liver disease Diseases 0.000 claims description 2
- 208000024908 graft versus host disease Diseases 0.000 claims description 2
- 206010023332 keratitis Diseases 0.000 claims description 2
- 208000019423 liver disease Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008494 pericarditis Diseases 0.000 claims description 2
- 239000000049 pigment Substances 0.000 claims description 2
- 201000007094 prostatitis Diseases 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 10
- 125000006588 heterocycloalkylene group Chemical group 0.000 claims 8
- 241000283690 Bos taurus Species 0.000 claims 4
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 4
- 206010010741 Conjunctivitis Diseases 0.000 claims 3
- 208000017604 Hodgkin disease Diseases 0.000 claims 3
- 125000002573 ethenylidene group Chemical group [*]=C=C([H])[H] 0.000 claims 3
- 208000005987 polymyositis Diseases 0.000 claims 3
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 201000002481 Myositis Diseases 0.000 claims 2
- 206010033645 Pancreatitis Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010035664 Pneumonia Diseases 0.000 claims 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
- 206010047115 Vasculitis Diseases 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 125000000732 arylene group Chemical group 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 230000001363 autoimmune Effects 0.000 claims 2
- 201000001981 dermatomyositis Diseases 0.000 claims 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 2
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 claims 2
- 206010015907 eye allergy Diseases 0.000 claims 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 206010028417 myasthenia gravis Diseases 0.000 claims 2
- 201000008383 nephritis Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 125000006413 ring segment Chemical group 0.000 claims 2
- 201000009890 sinusitis Diseases 0.000 claims 2
- 208000003265 stomatitis Diseases 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 125000006587 (C5-C10) heteroarylene group Chemical group 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000026872 Addison Disease Diseases 0.000 claims 1
- 208000003200 Adenoma Diseases 0.000 claims 1
- 206010001233 Adenoma benign Diseases 0.000 claims 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims 1
- 208000008884 Aneurysmal Bone Cysts Diseases 0.000 claims 1
- 208000032467 Aplastic anaemia Diseases 0.000 claims 1
- 206010003011 Appendicitis Diseases 0.000 claims 1
- 208000004736 B-Cell Leukemia Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006448 Bronchiolitis Diseases 0.000 claims 1
- 208000023611 Burkitt leukaemia Diseases 0.000 claims 1
- 206010006811 Bursitis Diseases 0.000 claims 1
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
- 208000006029 Cardiomegaly Diseases 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010008909 Chronic Hepatitis Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims 1
- 102100025621 Cytochrome b-245 heavy chain Human genes 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012468 Dermatitis herpetiformis Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 206010060742 Endocrine ophthalmopathy Diseases 0.000 claims 1
- 208000004145 Endometritis Diseases 0.000 claims 1
- 208000004232 Enteritis Diseases 0.000 claims 1
- 206010014950 Eosinophilia Diseases 0.000 claims 1
- 206010015218 Erythema multiforme Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 206010016228 Fasciitis Diseases 0.000 claims 1
- 206010016262 Fatty liver alcoholic Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000007882 Gastritis Diseases 0.000 claims 1
- 208000005577 Gastroenteritis Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000022461 Glomerular disease Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 206010018634 Gouty Arthritis Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 208000003807 Graves Disease Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 claims 1
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 claims 1
- 206010019755 Hepatitis chronic active Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000000203 Hyaline Membrane Disease Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- 208000031814 IgA Vasculitis Diseases 0.000 claims 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 208000026350 Inborn Genetic disease Diseases 0.000 claims 1
- 206010021639 Incontinence Diseases 0.000 claims 1
- 208000032571 Infant acute respiratory distress syndrome Diseases 0.000 claims 1
- 206010023347 Keratoacanthoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 206010023825 Laryngeal cancer Diseases 0.000 claims 1
- 201000008197 Laryngitis Diseases 0.000 claims 1
- 206010024238 Leptospirosis Diseases 0.000 claims 1
- 208000034624 Leukocytoclastic Cutaneous Vasculitis Diseases 0.000 claims 1
- 208000032514 Leukocytoclastic vasculitis Diseases 0.000 claims 1
- 208000004852 Lung Injury Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 206010052178 Lymphocytic lymphoma Diseases 0.000 claims 1
- 208000024556 Mendelian disease Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000005647 Mumps Diseases 0.000 claims 1
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 208000003926 Myelitis Diseases 0.000 claims 1
- 206010028974 Neonatal respiratory distress syndrome Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010029350 Neurotoxicity Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010031149 Osteitis Diseases 0.000 claims 1
- 208000010191 Osteitis Deformans Diseases 0.000 claims 1
- 208000005141 Otitis Diseases 0.000 claims 1
- 208000027868 Paget disease Diseases 0.000 claims 1
- 201000011152 Pemphigus Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 208000006735 Periostitis Diseases 0.000 claims 1
- 201000007100 Pharyngitis Diseases 0.000 claims 1
- 208000007452 Plasmacytoma Diseases 0.000 claims 1
- 206010065159 Polychondritis Diseases 0.000 claims 1
- 206010036105 Polyneuropathy Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 208000028561 Primary cutaneous T-cell lymphoma Diseases 0.000 claims 1
- 206010036774 Proctitis Diseases 0.000 claims 1
- 206010037596 Pyelonephritis Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 208000007893 Salpingitis Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 201000010208 Seminoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 230000006044 T cell activation Effects 0.000 claims 1
- 208000000491 Tendinopathy Diseases 0.000 claims 1
- 206010043255 Tendonitis Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 108090000190 Thrombin Proteins 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 206010044221 Toxic encephalopathy Diseases 0.000 claims 1
- 206010069363 Traumatic lung injury Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000008385 Urogenital Neoplasms Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000006374 Uterine Cervicitis Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010046914 Vaginal infection Diseases 0.000 claims 1
- 201000008100 Vaginitis Diseases 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- 208000016807 X-linked intellectual disability-macrocephaly-macroorchidism syndrome Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 206010069351 acute lung injury Diseases 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 201000005188 adrenal gland cancer Diseases 0.000 claims 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 208000030961 allergic reaction Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 210000003423 ankle Anatomy 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 208000018339 bone inflammation disease Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 206010008323 cervicitis Diseases 0.000 claims 1
- 208000003167 cholangitis Diseases 0.000 claims 1
- 201000001352 cholecystitis Diseases 0.000 claims 1
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 1
- 208000016532 chronic granulomatous disease Diseases 0.000 claims 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 claims 1
- 125000004976 cyclobutylene group Chemical group 0.000 claims 1
- FNIATMYXUPOJRW-UHFFFAOYSA-N cyclohexylidene Chemical group [C]1CCCCC1 FNIATMYXUPOJRW-UHFFFAOYSA-N 0.000 claims 1
- 125000004979 cyclopentylene group Chemical group 0.000 claims 1
- 125000004980 cyclopropylene group Chemical group 0.000 claims 1
- 201000003146 cystitis Diseases 0.000 claims 1
- 201000004400 dacryoadenitis Diseases 0.000 claims 1
- 230000001066 destructive effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 208000007784 diverticulitis Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000019258 ear infection Diseases 0.000 claims 1
- 208000002169 ectodermal dysplasia Diseases 0.000 claims 1
- 208000031068 ectodermal dysplasia syndrome Diseases 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 206010014665 endocarditis Diseases 0.000 claims 1
- 208000010227 enterocolitis Diseases 0.000 claims 1
- 201000010063 epididymitis Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 230000004578 fetal growth Effects 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 230000003325 follicular Effects 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 231100000852 glomerular disease Toxicity 0.000 claims 1
- 229930195712 glutamate Natural products 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 208000014951 hematologic disease Diseases 0.000 claims 1
- 208000007475 hemolytic anemia Diseases 0.000 claims 1
- 208000025070 hereditary periodic fever syndrome Diseases 0.000 claims 1
- 125000005549 heteroarylene group Chemical group 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 206010020718 hyperplasia Diseases 0.000 claims 1
- 201000006362 hypersensitivity vasculitis Diseases 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 claims 1
- 201000008319 inclusion body myositis Diseases 0.000 claims 1
- 208000015266 indolent plasma cell myeloma Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000026876 intravascular large B-cell lymphoma Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000003849 large cell carcinoma Diseases 0.000 claims 1
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000011486 lichen planus Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 231100000515 lung injury Toxicity 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000027202 mammary Paget disease Diseases 0.000 claims 1
- 208000004396 mastitis Diseases 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 208000010805 mumps infectious disease Diseases 0.000 claims 1
- 230000020763 muscle atrophy Effects 0.000 claims 1
- 201000000585 muscular atrophy Diseases 0.000 claims 1
- 231100000228 neurotoxicity Toxicity 0.000 claims 1
- 230000007135 neurotoxicity Effects 0.000 claims 1
- 201000002652 newborn respiratory distress syndrome Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 208000005963 oophoritis Diseases 0.000 claims 1
- 201000005737 orchitis Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 206010057056 paraneoplastic pemphigus Diseases 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 1
- 206010034674 peritonitis Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 1
- 208000001297 phlebitis Diseases 0.000 claims 1
- 208000008423 pleurisy Diseases 0.000 claims 1
- 230000007824 polyneuropathy Effects 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 201000003774 sarcomatosis Diseases 0.000 claims 1
- 239000000377 silicon dioxide Substances 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 230000000391 smoking effect Effects 0.000 claims 1
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 claims 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 210000004243 sweat Anatomy 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 201000004415 tendinitis Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 229960004072 thrombin Drugs 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 206010043778 thyroiditis Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 206010044008 tonsillitis Diseases 0.000 claims 1
- 230000008736 traumatic injury Effects 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046885 vaginal cancer Diseases 0.000 claims 1
- 208000013139 vaginal neoplasm Diseases 0.000 claims 1
- 208000002003 vulvitis Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 6
- 238000006731 degradation reaction Methods 0.000 abstract description 6
- 230000001588 bifunctional effect Effects 0.000 abstract description 3
- 108090001005 Interleukin-6 Proteins 0.000 abstract description 2
- 208000026278 immune system disease Diseases 0.000 abstract description 2
- 210000002865 immune cell Anatomy 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 description 197
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 149
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 138
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 132
- 239000001301 oxygen Substances 0.000 description 132
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 130
- 239000011593 sulfur Chemical group 0.000 description 130
- 229920006395 saturated elastomer Polymers 0.000 description 112
- 230000004481 post-translational protein modification Effects 0.000 description 69
- 125000000623 heterocyclic group Chemical group 0.000 description 67
- 125000001188 haloalkyl group Chemical group 0.000 description 54
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 43
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 description 41
- 125000006545 (C1-C9) alkyl group Chemical group 0.000 description 37
- MPVDXIMFBOLMNW-UHFFFAOYSA-N chembl1615565 Chemical compound OC1=CC=C2C=C(S(O)(=O)=O)C=C(S(O)(=O)=O)C2=C1N=NC1=CC=CC=C1 MPVDXIMFBOLMNW-UHFFFAOYSA-N 0.000 description 35
- 125000004433 nitrogen atom Chemical group N* 0.000 description 30
- 125000003545 alkoxy group Chemical group 0.000 description 29
- 229910052799 carbon Inorganic materials 0.000 description 28
- 229910052701 rubidium Inorganic materials 0.000 description 28
- 125000004432 carbon atom Chemical group C* 0.000 description 27
- 239000000460 chlorine Substances 0.000 description 27
- 125000006677 (C1-C3) haloalkoxy group Chemical group 0.000 description 24
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 23
- 125000002950 monocyclic group Chemical group 0.000 description 23
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 22
- 125000006647 (C3-C15) cycloalkyl group Chemical group 0.000 description 22
- 125000003342 alkenyl group Chemical group 0.000 description 22
- 125000004404 heteroalkyl group Chemical group 0.000 description 22
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 21
- 125000003709 fluoroalkyl group Chemical group 0.000 description 20
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 20
- 125000003107 substituted aryl group Chemical group 0.000 description 20
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 19
- 229910002092 carbon dioxide Inorganic materials 0.000 description 19
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 19
- 229910052794 bromium Inorganic materials 0.000 description 18
- 229910017711 NHRa Inorganic materials 0.000 description 17
- 125000002252 acyl group Chemical group 0.000 description 14
- 125000000547 substituted alkyl group Chemical group 0.000 description 14
- 125000002947 alkylene group Chemical group 0.000 description 13
- 125000000304 alkynyl group Chemical group 0.000 description 13
- 150000002430 hydrocarbons Chemical group 0.000 description 12
- 229910052740 iodine Inorganic materials 0.000 description 12
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 12
- 229910052705 radium Inorganic materials 0.000 description 12
- 150000001721 carbon Chemical group 0.000 description 11
- 150000002148 esters Chemical class 0.000 description 11
- 125000003566 oxetanyl group Chemical group 0.000 description 11
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 10
- 125000003226 pyrazolyl group Chemical group 0.000 description 10
- 125000000714 pyrimidinyl group Chemical group 0.000 description 10
- 229910003827 NRaRb Inorganic materials 0.000 description 9
- 125000005843 halogen group Chemical group 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 9
- 229940124823 proteolysis targeting chimeric molecule Drugs 0.000 description 9
- 150000001408 amides Chemical group 0.000 description 8
- 125000002837 carbocyclic group Chemical group 0.000 description 8
- 125000002757 morpholinyl group Chemical group 0.000 description 8
- 238000011865 proteolysis targeting chimera technique Methods 0.000 description 8
- 230000019491 signal transduction Effects 0.000 description 8
- 108010026668 snake venom protein C activator Proteins 0.000 description 8
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 8
- 102000002689 Toll-like receptor Human genes 0.000 description 7
- 108020000411 Toll-like receptor Proteins 0.000 description 7
- 125000001931 aliphatic group Chemical group 0.000 description 7
- 125000004103 aminoalkyl group Chemical group 0.000 description 7
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 7
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 7
- 125000006592 (C2-C3) alkenyl group Chemical group 0.000 description 6
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 6
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 6
- 108091000080 Phosphotransferase Proteins 0.000 description 6
- 125000000392 cycloalkenyl group Chemical group 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 125000002883 imidazolyl group Chemical group 0.000 description 6
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 description 6
- 102000020233 phosphotransferase Human genes 0.000 description 6
- 125000003003 spiro group Chemical group 0.000 description 6
- 229910052727 yttrium Inorganic materials 0.000 description 6
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 description 5
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 description 5
- 125000005915 C6-C14 aryl group Chemical group 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 5
- 125000004438 haloalkoxy group Chemical group 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 description 4
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 4
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 4
- 125000004450 alkenylene group Chemical group 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 4
- 229940124530 sulfonamide Drugs 0.000 description 4
- 150000003456 sulfonamides Chemical class 0.000 description 4
- 125000001425 triazolyl group Chemical group 0.000 description 4
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 description 3
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 3
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 125000005600 alkyl phosphonate group Chemical group 0.000 description 3
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 3
- 125000001841 imino group Chemical group [H]N=* 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 3
- 125000001715 oxadiazolyl group Chemical group 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 3
- 125000005415 substituted alkoxy group Chemical group 0.000 description 3
- 125000006699 (C1-C3) hydroxyalkyl group Chemical group 0.000 description 2
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 2
- 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 description 2
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 description 2
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 2
- 125000006375 C2-C10 alkynyl group Chemical group 0.000 description 2
- 208000000094 Chronic Pain Diseases 0.000 description 2
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 208000004483 Dyspareunia Diseases 0.000 description 2
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 208000004454 Hyperalgesia Diseases 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 2
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 2
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 2
- 229910004749 OS(O)2 Inorganic materials 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 229910019999 S(O)2O Inorganic materials 0.000 description 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 125000005257 alkyl acyl group Chemical group 0.000 description 2
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 2
- 125000002393 azetidinyl group Chemical group 0.000 description 2
- 125000005605 benzo group Chemical group 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 125000004966 cyanoalkyl group Chemical group 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000006310 cycloalkyl amino group Chemical group 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 2
- 125000004428 fluoroalkoxy group Chemical group 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 108040006732 interleukin-1 receptor activity proteins Proteins 0.000 description 2
- 102000014909 interleukin-1 receptor activity proteins Human genes 0.000 description 2
- 208000028774 intestinal disease Diseases 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 2
- 125000006574 non-aromatic ring group Chemical group 0.000 description 2
- 125000005010 perfluoroalkyl group Chemical group 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000004929 pyrrolidonyl group Chemical group N1(C(CCC1)=O)* 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 229910052702 rhenium Inorganic materials 0.000 description 2
- 229910052703 rhodium Inorganic materials 0.000 description 2
- 201000005671 spondyloarthropathy Diseases 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 150000007970 thio esters Chemical class 0.000 description 2
- 125000004149 thio group Chemical group *S* 0.000 description 2
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 1
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 description 1
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 description 1
- 125000006736 (C6-C20) aryl group Chemical group 0.000 description 1
- 125000004530 1,2,4-triazinyl group Chemical group N1=NC(=NC=C1)* 0.000 description 1
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- PXAWSYHMHMFXBD-GOSISDBHSA-N 4-(cyclopropylamino)-n-[(2r)-2-fluoro-3-hydroxy-3-methylbutyl]-6-(1,6-naphthyridin-2-ylamino)pyridine-3-carboxamide Chemical compound CC(C)(O)[C@H](F)CNC(=O)C1=CN=C(NC=2N=C3C=CN=CC3=CC=2)C=C1NC1CC1 PXAWSYHMHMFXBD-GOSISDBHSA-N 0.000 description 1
- DGHJKOUXAHNRAP-UHFFFAOYSA-N 4-methyloxadiazole Chemical compound CC1=CON=N1 DGHJKOUXAHNRAP-UHFFFAOYSA-N 0.000 description 1
- RWIMETUXCNDSLE-UHFFFAOYSA-N 6-(6-aminopyridin-3-yl)-N-(2-morpholin-4-yl-[1,3]oxazolo[4,5-b]pyridin-6-yl)pyridine-2-carboxamide Chemical compound NC1=CC=C(C=N1)C1=NC(=CC=C1)C(=O)NC=1C=C2C(=NC1)N=C(O2)N2CCOCC2 RWIMETUXCNDSLE-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000005641 Adenomyosis Diseases 0.000 description 1
- 208000026326 Adult-onset Still disease Diseases 0.000 description 1
- 102100032187 Androgen receptor Human genes 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- JKDGKIBAOAFRPJ-ZBINZKHDSA-N C(C)[C@H]1[C@H](NC([C@H]1F)=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N Chemical compound C(C)[C@H]1[C@H](NC([C@H]1F)=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N JKDGKIBAOAFRPJ-ZBINZKHDSA-N 0.000 description 1
- 125000000172 C5-C10 aryl group Chemical group 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000010170 Death domains Human genes 0.000 description 1
- 108050001718 Death domains Proteins 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 208000007465 Giant cell arteritis Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 101000852483 Homo sapiens Interleukin-1 receptor-associated kinase 1 Proteins 0.000 description 1
- 101000852255 Homo sapiens Interleukin-1 receptor-associated kinase-like 2 Proteins 0.000 description 1
- 101000852965 Homo sapiens Interleukin-1 receptor-like 2 Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 1
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 229940099539 IL-36 receptor antagonist Drugs 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 102100020881 Interleukin-1 alpha Human genes 0.000 description 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 1
- 102100036342 Interleukin-1 receptor-associated kinase 1 Human genes 0.000 description 1
- 102100036433 Interleukin-1 receptor-associated kinase-like 2 Human genes 0.000 description 1
- 102100036697 Interleukin-1 receptor-like 2 Human genes 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 description 1
- 208000034607 Kindler epidermolysis bullosa Diseases 0.000 description 1
- 201000004290 Kindler syndrome Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
- 102100026888 Mitogen-activated protein kinase kinase kinase 7 Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000007201 Myocardial reperfusion injury Diseases 0.000 description 1
- OQAMEEFUUFJZRS-UHFFFAOYSA-N N-[6-(2-hydroxypropan-2-yl)-2-(2-methylsulfonylethyl)indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide Chemical compound OC(C)(C)C=1C(=CC2=CN(N=C2C=1)CCS(=O)(=O)C)NC(=O)C1=NC(=CC=C1)C(F)(F)F OQAMEEFUUFJZRS-UHFFFAOYSA-N 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 229910003204 NH2 Inorganic materials 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 1
- 229920001774 Perfluoroether Polymers 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 206010065347 Premenstrual pain Diseases 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 229910006069 SO3H Inorganic materials 0.000 description 1
- 101710204410 Scaffold protein Proteins 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 1
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 1
- 102100024324 Toll-like receptor 3 Human genes 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 208000001445 Uveomeningoencephalitic Syndrome Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000034705 Vogt-Koyanagi-Harada syndrome Diseases 0.000 description 1
- LELQZCNRZHLYFG-ZDVGBALWSA-N [(4e,7e)-trideca-4,7-dienyl] acetate Chemical compound CCCCC\C=C\C\C=C\CCCOC(C)=O LELQZCNRZHLYFG-ZDVGBALWSA-N 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003302 alkenyloxy group Chemical group 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 125000004419 alkynylene group Chemical group 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 208000002029 allergic contact dermatitis Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 206010053552 allodynia Diseases 0.000 description 1
- 125000006598 aminocarbonylamino group Chemical group 0.000 description 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 125000005873 benzo[d]thiazolyl group Chemical group 0.000 description 1
- 125000006580 bicyclic heterocycloalkyl group Chemical group 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- CISNNLXXANUBPI-UHFFFAOYSA-N cyano(nitro)azanide Chemical compound [O-][N+](=O)[N-]C#N CISNNLXXANUBPI-UHFFFAOYSA-N 0.000 description 1
- 125000004802 cyanophenyl group Chemical group 0.000 description 1
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 description 1
- 125000005144 cycloalkylsulfonyl group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 201000009274 endometriosis of uterus Diseases 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000011737 fluorine Chemical group 0.000 description 1
- 235000019000 fluorine Nutrition 0.000 description 1
- 125000005348 fluorocycloalkyl group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 125000005347 halocycloalkyl group Chemical group 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 1
- 201000007162 hidradenitis suppurativa Diseases 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 102000008625 interleukin-18 receptor activity proteins Human genes 0.000 description 1
- 108040002014 interleukin-18 receptor activity proteins Proteins 0.000 description 1
- 108040007659 interleukin-33 receptor activity proteins Proteins 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 150000002825 nitriles Chemical group 0.000 description 1
- MGQNMYSRDBFUIR-UHFFFAOYSA-N nitro cyanoformate Chemical compound [O-][N+](=O)OC(=O)C#N MGQNMYSRDBFUIR-UHFFFAOYSA-N 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000009038 pharmacological inhibition Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 230000001185 psoriatic effect Effects 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 208000032253 retinal ischemia Diseases 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 206010043207 temporal arteritis Diseases 0.000 description 1
- 108091008743 testicular receptors 4 Proteins 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000004001 thioalkyl group Chemical group 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 230000006663 ubiquitin-proteasome pathway Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention belongs to the field of pharmaceuticals, and in particular, the present invention relates to compounds for targeting and degrading IRAK4 proteins, pharmaceutical compositions and methods therefor and their use in the preparation of medicaments for the treatment and/or prevention of related diseases or conditions mediated by IRAK4, such as cancer, immune diseases and inflammatory diseases.
- Interleukin-1 receptor kinase 4 (IRAK4) is a serine/threonine-specific protein kinase with biologically important kinase activity and plays an important role in activating the immune system.
- IRAK4 is a key factor downstream of IL-1 ⁇ family receptors (including IL-1R, IL-18R, IL-33R, IL-36R) and Toll-like receptor (TLR) signaling pathways.
- TLR Toll-like receptor
- TLR/IL-1 ⁇ and IL-1 ⁇ mediated signaling pathways can be divided into MyD88-dependent signaling pathways and MyD88-independent pathways, in which IL-1R and TLR2, TLR4, TLR7/8, TLR9 mediated signal transduction pathways rely on MyD88 as a regulator to activate downstream inflammatory signaling pathways.
- TLR/IL-1 ⁇ binds to the ligand
- MyD88 molecules are recruited, then MyD88 further recruits IRAK4 into TLR/IL-1 ⁇ complex through its N-terminal death domain, and interacts with IRAK1 or IRAK2 and activates it, thus transmitting signals to E3 ubiquitin ligase TNF receptor related factor (TRAF6) downstream, activating serine/threonine kinase TAK1, and then activating NF- ⁇ B and MAPK signal pathways, thus causing the release of a variety of inflammatory cytokines and anti-apoptotic molecules.
- TNF receptor related factor ubiquitin ligase TNF receptor related factor
- the IRAK4-dependent TLR/IL-1 ⁇ signaling pathway has been shown to be associated with a variety of diseases: such as multiple sclerosis, atherosclerosis, myocardial infarction, myocarditis, Vogt-Koyanagi-Harada syndrome, systemic lupus erythematosus (SLE), obesity, type 1 diabetes, rheumatoid arthritis, spondyloarthritis (especially psoriatic spondyloarthritis and Bekhterev's disease), lupus erythematosus, psoriasis, vitiligo, giant cell arteritis, chronic inflammatory intestinal diseases and viral diseases, for example, HIV (human immunodeficiency virus), hepatitis virus; Skin diseases such as psoriasis, atopic dermatitis, Kindler's syndrome, bullous pemphigoid, allergic contact dermatitis, alopecia areata, acnein
- IRAK4-mediated signaling pathway The regulation of IRAK4-mediated signaling pathway is mainly related to its kinase function. However, there are also some reports indicating in some cell types, the signal regulation of downstream processes by IRAK4 is related to the non-kinase function of IRAK4. Cushing et al. indicated that although the phosphorylation level of IRAK4 was reduced in human skin fibroblasts stimulated by IL-1 ⁇ , the pharmacological inhibition of IRAK4 does not lead to the inhibition of IL-6 and TNF- ⁇ . In support of these results, the scaffold function of IRAK4 is important for IL1 signaling in IRAK4-deficient fibroblasts compared with wild-type cells, but its kinase effect is redundant.
- IRAK4 kinase activity was not necessary in human B cells, T cells, dendritic cells and monocytes, and siRNA gene excision also showed that IRAK4 had a scaffold function in these cells.
- a variety of potent selective inhibitors against IRAK4 have been reported, such as CA-4948, BAY-1834845, BMS-986126 and PF-06650833. These inhibitors can selectively inhibit the kinase activity of IRAK4 and are mainly used for the prevention and treatment of autoimmune diseases, inflammatory diseases and tumor diseases.
- IRAK4 has the function of scaffold protein and active kinase, and on the other hand, traditional small molecule inhibitors are prone to drug resistance, therefore, only inhibition of IRAK4 kinase activity may not be sufficient to produce therapeutic effect.
- Proteolysis Targeting Chimera is a technology different from traditional small molecule inhibitors.
- Traditional small molecule inhibitors usually need to act on the active site of the target protein to inhibit its activity.
- PROTAC is a heterogeneous bifunctional molecule, one end of which is a small molecule inhibitor that can recognize the target protein. Through the connection chain, the other end is an E3 ubiquitin ligase ligand that can recognize E3 ubiquitin ligase, this bifunctional molecule recognizes the target protein and E3 ubiquitin ligase in the body, and draws the target protein and E3 ubiquitin ligase closer to form a ternary complex.
- the target protein After the target protein is ubiquitinated, the target protein is degraded through the ubiquitin-proteasome pathway in the body.
- PROTAC only needs to bring the target protein closer to E3 ubiquitin ligase to degrade the substrate, and this mode of action makes this technology applicable to some non-druggable targets;
- the PROTAC molecules can be released to continue to participate in the degradation process of the next protein, so this degradation has a catalytic effect, so that less dose of PROTAC drug can achieve efficient degradation;
- traditional small molecule inhibitors are often prone to drug resistance because of point mutations, which makes small molecule inhibitors lose the inhibitory effect on the target.
- PROTAC can directly degrade the target protein, which can avoid the drug resistance caused by point mutations to a certain extent. Therefore, compared with traditional small molecule inhibitors, the use of PROTAC technology for new drug small molecule research and development has high advantages and feasibility, and is expected to become the next generation of promising new drugs.
- PROTAC technology has also been applied to the modification of various target drugs, such as androgen receptor, estrogen protein receptor, BTK, etc.
- target drugs such as androgen receptor, estrogen protein receptor, BTK, etc.
- Several types of degradation agents targeting IRAK4 are disclosed in US2019/0151295 , US2019/0192688 , WO2019/160915 and WO2020/113233 , and more degradation agents targeting IRAK4 are to be developed.
- the invention provides a compound of formula I, and/or a stereoisomer, an enantiomer, a diastereomer, a deuterate, a hydrate, a solvate, a prodrug and/or a pharmaceutically acceptable salt thereof: PTM-L-ULM I wherein:
- one or two of Q 1 , Q 2 , Q 3 , Q 4 and Q 5 in ULM-1 are N, and the rest are each independently CR 3 ".
- Q 1 , Q 2 , Q 3 , Q 4 and Q 5 in ULM-1 are each independently CR 3 ".
- X" in ULM-1 is N.
- X" in ULM-1 is CH.
- Y" in ULM-1 is N.
- R 1 " in ULM-1 is each independently hydrogen, deuterium, -F, -Cl, or C1-C6 alkyl, the alkyl is optionally substituted by 1-3 halogens; preferably R 1 " is hydrogen.
- R 2 " in ULM-1 is hydrogen or C1-C6 alkyl, the alkyl is optionally substituted by 1-3 halogens; preferably R 2 " is hydrogen.
- R 3 "in ULM-1 is each independently hydrogen, deuterium, halogen, -O(C1-C6 alkyl), or C1-C6 alkyl, the alkyl is optionally substituted by 1-3 halogens; preferably R 3 " is each independently hydrogen, deuterium, F, Cl, methyl, methoxy, ethoxy, trifluoromethoxy, 2-hydroxypropyl-2-yl or trifluoromethyl.
- the ULM-1 is connected to L via Q 1 , Q 2 , Q 3 , Q 4 or Q 5 .
- the ULM has the following structure: wherein, Q 1 , Q 2 , Q 3 , Q 4 , Q 5 , R 1 ", R 2 "and m" are as defined in the above ULM-1.
- the ULM has the following structure: wherein, R 1 ", R 2 “, R 3 ", and m" are as defined in the above ULM-1.
- the ULM has the following structure: wherein, R 1 ", R 2 " and R 3 " are as defined in the above ULM-1.
- the ULM has the following structure: wherein, R 3 " is as defined in the above ULM-1.
- the ULM has the following structure: wherein, Q 1 , Q 2 , Q 3 , Q 5 , R 1 ", R 2 " and m" are as defined in the above ULM-1.
- the ULM has the following structure: wherein, R 1 ", R 2 “, R 3 ", and m" are as defined in the above ULM-1.
- the ULM has the following structure: wherein, R 1 ", R 2 ", R 3 " are as defined in the above ULM-1. wherein, R 3 " is as defined in the above ULM-1.
- the ULM is selected from or
- the ULM is selected from
- the ULM has the following structure: wherein, Q 1 , Q 2 , Q 3 , Q 4 , Qs, R 1 ", R 2 "and m" are as defined in the above ULM-1.
- the ULM has the following structure: wherein, R 1 ", R 2 “, R 3 ", and m" are as defined in the above ULM-1.
- the ULM has the following structure: wherein, R 1 ", R 2 " and R 3 " are as defined in the above ULM-1.
- the ULM has the following structure: wherein, R 3 " is as defined in the above ULM-1.
- the ULM has the following structure: wherein, Q 1 , Q 2 , Q 3 , Q 5 , R 1 ", R 2 " and m" are as defined in the above ULM-1.
- the ULM has the following structure: wherein, R 1 ", R 2 “, R 3 ", and m" are as defined in the above ULM-1.
- the ULM has the following structure: wherein, R 1 ", R 2 " and R 3 " are as defined in the above ULM-1. wherein, R 3 " is as defined in the above ULM-1.
- the ULM is selected from or
- the ULM is selected from
- the compound of formula I, and/or stereoisomer, enantiomer, diastereomer, deuterate, metabolite, hydrate, solvate, prodrug and/or pharmaceutically acceptable salt thereof is a compound of formula Ia, and/or a stereoisomer, an enantiomer, a diastereomer, a deuterate, a metabolite, a hydrate, a solvate, a prodrug and/or a pharmaceutically acceptable salts thereof, wherein, Q 1 , Q 2 , Q 3 , Q 4 , Q 5 , R 1 ", R 2 ", m", X", and Y" are as defined in ULM-1, and L, PTM are as defined herein.
- the PTM has the following structure:
- the PTM has the following structure: or a pharmaceutically acceptable salt thereof; wherein, in PTM-70, PTM-70a, PTM-70b or PTM-70c:
- the PTM is selected from
- the PTM has the following structure:
- the compound of formula I, and/or stereoisomer, enantiomer, diastereomer, deuterate, metabolite, hydrate, solvate, prodrug thereof and/or pharmaceutically acceptable salt thereof is a compound of formula IA, and/or stereoisomer, enantiomer, diastereomer, deuterate, metabolite, hydrate, solvate, prodrug thereof and/or pharmaceutically acceptable salt thereof, wherein, X 1 , X 2 , X 3 , A, Y, p, R 1 , R 3 , m, Z, n are as defined in PTM-70, and L, ULM are as defined herein.
- the compound of formula I, and/or a stereoisomer, enantiomer, diastereomer, deuterate, metabolite, hydrate, solvate, prodrug thereof and/or its pharmaceutically acceptable salt thereof is a compound of formula IA-1, and/or stereoisomer, enantiomer, diastereomer, deuterate, metabolite, hydrate, solvate, prodrug thereof and/or pharmaceutically acceptable salt thereof, wherein, A, Y, p, R 1 , R 2 , R 3 , m, n are as defined in PTM-70a, and L, ULM are as defined herein.
- the compound of formula I, and/or stereoisomer, enantiomer, diastereomer, deuterate, metabolite, hydrate, solvate, prodrug thereof and/or pharmaceutically acceptable salt thereof is a compound of formula IA-2, and/or stereoisomer, enantiomer, diastereomer, deuterate, metabolite, hydrate, solvate, prodrug thereof and/or pharmaceutically acceptable salt thereof, wherein, A, Y, R 1 , R 2 , n are as defined in PTM-70b, and L, ULM are as defined herein.
- the compound of formula I, and/or stereoisomer, enantiomer, diastereomer, deuterate, metabolite, hydrate, solvate, prodrug thereof and/or pharmaceutically acceptable salt thereof is a compound of formula IA-3, and/or its stereoisomer, enantiomer, diastereomer, deuterate, metabolite, hydrate, solvate, prodrug thereof and/or pharmaceutically acceptable salt thereof, wherein: A, Y, R 1 , R 2 , n are as defined in PTM-70c, and L, ULM are as defined herein.
- the PTM has the following structure: or a pharmaceutically acceptable salt thereof; wherein, in PTM-69h or PTM-69i:
- R 1 is C1-C6 alkyl optionally substituted by 1-3 deuteriums, fluorines, chlorines or C1-C3 alkoxyls; preferably R 1 is methyl, ethyl, propyl or isopropyl, wherein each R 1 is optionally substituted by deuterium, fluorine or methoxy.
- R 3a and R 3b are independently hydrogen or methyl at each occurrence.
- R 4 is independently fluorine, chlorine, hydroxyl, or C1-C3 alkyl optionally substituted by 1-5 deuterated, fluorine, chlorine, hydroxyl or C1-C3 alkoxy at each occurrence, or two R 4 together with the carbon atom to which they are attached form cyclopropyl, cyclobutyl or cyclopentyl, the cyclopropyl, cyclobutyl and cyclopentyl are optionally substituted by 1-3 fluorine, chlorine, hydroxyl, methyl, ethyl, propyl, C1-C3 hydroxylalkyl, C1-C3 fluoroalkyl, C1-C3 difluoroalkyl, C1-C3 trifluoroalkyl, methoxy or ethoxy; preferably R 4 is independently fluorine, hydroxyl, methyl, ethyl, propyl at each
- R 8 is each independently hydrogen, deuterium, halogen or C1-C6 alkyl, wherein the alkyl is optionally substituted by fluorine; preferably R 8 is each independently hydrogen, deuterium, fluorine or methyl.
- R 8 is each independently C2-6 alkenyl or C2-6 alkynyl, wherein the alkenyl, alkynyl are optionally substituted by C3-C6 cycloalkyl, C3-C6 heterocycloalkyl containing 1 or 2 N heteroatoms; preferably R 8 is each independently vinyl, ethynyl, and optionally substituted by cyclohexanyl, piperidinyl or piperazinyl.
- R 4a is hydrogen, deuterium, methyl, ethyl or propyl optionally substituted by fluorine, deuterium or methoxy.
- R 4b is hydrogen or fluorine.
- R 4c is hydroxyl
- R 4d is fluorine, methoxy or hydroxyl, or methyl optionally substituted by one, two or three fluoros, or ethyl optionally substituted by one, two or three fluoros.
- R 4c and R 4a or R 4c and R 4d together with the carbon atoms to which they are attached form cyclopropyl optionally substituted by 1-3 fluorine, C1-C3 alkyl or C1-C3 fluoroalkyl.
- the PTM is selected from
- the PTM is selected from
- the PTM is selected from or
- the compound of formula I, and/or a stereoisomer, enantiomer, diastereomer, deuterate, metabolite, hydrate, solvate, prodrug thereof and/or a pharmaceutically acceptable salt thereof is a compound of formula IB, and/or a stereoisomer, enantiomer, diastereomer, deuterate, metabolite, hydrate, solvate, prodrug thereof and/or a pharmaceutically acceptable salt thereof, wherein: X, X', Y, R 1 , R 4 , R 3a , R 3b , R 8 , n are as defined in PTM-69h, and L, ULM are as defined herein.
- the compound of formula I, and/or a stereoisomer, enantiomer, diastereomer, deuterate, metabolite, hydrate, solvate, prodrug thereof and/or pharmaceutically acceptable salt thereof is a compound of formula IB-1, and/or a stereoisomer, enantiomer, diastereomer, deuterate, metabolite, hydrate, solvate, prodrug thereof and/or a pharmaceutically acceptable salt thereof, wherein: X, X', Y, R 1 , R 4a , R 4b , R 4c , R 4d , R 3a , R 3b , R 8 , n are as defined in PTM-69i, and L, ULM are as defined herein.
- the PTM has the following structure: wherein, in PTM-71:
- the PTM has the following structure wherein, in PTM-71:
- ring A is pyridyl
- R d is each independently hydrogen, deuterium, halogen or C1-C6 alkyl, optionally substituted by one or more groups selected from halogen or hydroxyl; preferably R d is hydrogen, deuterium, F, methyl, difluoromethyl, trifluoromethyl or 2-hydroxypropyl.
- R e is hydrogen
- R c is C1-C6 alkyl, the alkyl is optionally substituted by one or more groups independently selected from hydroxyl and halogen; preferably R c is difluoromethyl or 2-hydroxypropyl.
- R c is -O(C1-C6 alkyl), the alkyl is optionally substituted by one or more groups independently selected from hydroxyl, halogen or -OCH 3 ; preferably R c is methoxy, ethoxy, isopropoxy, -OCH 2 CH 2 OCH 3 , difluoromethoxy or trifluoromethoxy.
- R c is -O-(3-6-membered heterocycloalkyl containing 1 or 2 heteroatoms selected from N or O); preferably
- R b is hydrogen or methyl
- R a is hydrogen
- R a is 3-8-membered heterocycloalkyl containing 1 or 2 heteroatoms selected from N, O or S, the heterocycloalkyl is optionally substituted by one or more groups selected from hydroxyl, halogen, amino, cyano, C1-C6 alkyl,-O(Cl-C6 alkyl), halogenated C1-C6 alkyl, hydroxyl C1-C6 alkyl, amino C1-C6 alkyl; preferably R a is 3-8-membered heterocycloalkyl containing 1 or 2 heteroatoms selected from N or O, the heterocycloalkyl is optionally substituted by one or more groups selected from hydroxyl, halogen, amino, cyano, C1-C6 alkyl,-O(C1-C6 alkyl), halogenated C1-C6 alkyl, hydroxyl C1-C6 alkyl, amino C1-C6 alkyl;
- R a is cyclohexane, and the cyclohexane is optionally substituted by one or more groups selected from hydroxyl, halogen, amino, cyano, C1-C6 alkyl,-O(Cl-C6 alkyl), halogenated C1-C6 alkyl, hydroxyl C1-C6 alkyl, amino C1-C6 alkyl, preferably optionally substituted by one or more groups selected from hydroxyl, amino, methyl, methoxy, hydroxymethyl, trifluoromethyl.
- R a is hydrogen or C1-C6 alkyl
- the C1-C6 alkyl is optionally substituted by one or more groups selected from F, hydroxyl, methoxy, fluoromethoxy,-S(O) 2 CH 3 ,-S(O) 2 -cyclopropyl, cyclopropyl, and oxetanyl.
- PTM has the following structure: wherein, R a , R b , R c , R d , and R e are as defined in the above PTM-71.
- PTM has the following structure: wherein, R a , R b , R c , R d , R e , and n are as defined in the above PTM-71.
- PTM has the following structure: wherein, R b , R c , R d , and R e are as defined in the above PTM-71.
- PTM has the following structure: wherein, R b , R c , R d , and R e are as defined in the above PTM-71.
- PTM has the following structure: wherein, R b , R c , R d , and R e are as defined in the above PTM-71.
- PTM has the following structure: wherein, R b , R c , R d , and R e are as defined in the above PTM-71.
- the PTM is selected from or
- the PTM is selected from
- the PTM is selected from
- the compound of formula I, and/or a stereoisomer, enantiomer, diastereomer, deuterate, metabolite, hydrate, solvate, prodrug thereof and/or pharmaceutically acceptable salt thereof is a compound of formula IC, and/or a stereoisomer, enantiomer, diastereomer, deuterate, metabolite, hydrate, solvate, prodrug thereof and/or pharmaceutically acceptable salt thereof, wherein, ring A, R a , R b , R c , R d , R e , and n are as defined in PTM-71, and L, ULM are as defined herein.
- the compound of formula I, and/or a stereoisomer, enantiomer, diastereomer, deuterate, metabolite, hydrate, solvate, prodrug thereof and/or a pharmaceutically acceptable salt thereof is a compound of formula IC-1, and/or a stereoisomer, enantiomer, diastereomer, deuterate, metabolite, hydrate, solvate, prodrug thereof and/or a pharmaceutically acceptable salt thereof, wherein, R a , R b , R c , R d , and R e are as defined in PTM-71, and L, ULM are as defined herein.
- the compound of formula I, and/or a stereoisomer, enantiomer, diastereomer, deuterate, metabolite, hydrate, solvate, prodrug thereof and/or a pharmaceutically acceptable salt thereof is a compound of formula IC-2, and/or a stereoisomer, enantiomer, diastereomer, deuterate, metabolite, hydrate, solvate, prodrug thereof and/or a pharmaceutically acceptable salt thereof, wherein, R b , R c , R d , R e are as defined in PTM-71, and L, ULM are as defined herein.
- the compound of formula I, and/or a stereoisomer, enantiomer, diastereomer, deuterate, metabolite, hydrate, solvate, prodrug thereof and/or a pharmaceutically acceptable salt thereof is a compound of formula IC-3, and/or a stereoisomer, enantiomer, diastereomer, deuterate, metabolite, hydrate, solvate, prodrug thereof and/or a pharmaceutically acceptable salt thereof, wherein, R b , R c , R d , R e are as defined in PTM-71, and L, ULM are as defined herein.
- L is bond
- L is -(CH 2 ) j -, one or more methylenes in -(CH 2 ) j - are optionally replaced by groups selected from -NR 3 ' -,-O-,-S-,-S(O)-,-S(O)NR 3' -,-NR 3 ' S(O)-,-S(O) 2 -,-S(O) 2 NR 3' -,-NR 3 ' S(O) 2 -,-NR 4' S(O) 2 NR 3 ' -,-CR 1' R 2' -,-C(O)-,-C(O)O-,-OC(O)-,-NR 3' C(O)O-,-OC(O)NR 3 ' -,-C(O)NR 3 ' -,-NR 3 ' C(O)NR 3 ' -,-NR 3 ' C(O)NR 3 ' -,-NR 3 ' C(O)NR 3 ' -,
- L is -(CH 2 ) j -, one or more methylenes in -(CH 2 ) j - are optionally replaced by groups selected from -NR 3 ' -,-O-,-CR 1' R 2 ' -,-C(O)-,-S(O)-,-S(O) 2 -,-C(O)O-,-OC(O)-,-C(O)NR 3' -,-NR 3 ' C(O)-,-S(O) 2 NR 3' -,-NR 3 ' S(O) 2 -, vinylidene, ethynylene, phenyl, 8-10 membered bicycloarylene, 3-7 membered saturated or partially unsaturated cycloalkylene, 4-11 membered saturated or partially unsaturated spiro cycloalkylene, 4-11-membered saturated or partially unsaturated fused cycloalkylene, 8
- L is -(CH 2 ) j -, one or more methylenes in -(CH 2 ) j - are optionally replaced by groups selected from -NR 3 '-,-O-,-CR 1' R 2 ' -,-C(O)-,-S(O)-,-S(O) 2 -,-C(O)O-,-OC(O)-,-C(O)NR 3' -,-NR 3 ' C(O)-,-S(O) 2 NR 3' -,-NR 3 ' S(O) 2 -, vinylidene, ethynylene, phenyl, 8-10 membered bicyclic arylene, 3-7 membered saturated or partially unsaturated monocyclic cycloalkylene, 4-11 membered saturated or partially unsaturated spiro cycloalkylene, 4-11-membered saturated or partially unsaturated fused cycloalky
- L is -(CH2)j, 1, 2, 3 or 4 methylenes in -(CH2)j- are optionally replaced by a group selected from -NH-, -NCH3-, - NCH2CH3-, -O-, -C(CH3)2-, -CHF-, -CHCF3-, -C(O)-, -C(O)O-, -OC(O)-, -C(O)NH-, - C(O)NCH3-, -NHC(O)-, -NCH3C(O)-, vinylidene, ethynylene, cyclopropylene, cyclobutylene, cyclopentylene, cyclohexylidene, oxiranylene, oxetanylene, oxolanylene, oxanilene, azridinylene, azetidinylene, azacyclopent
- L is -(CH2)j, 1, 2 or 3 methylenes in -(CH2)j- are optionally replaced by a group selected from -NH-, -NCH3-, - NCH2CH3-, -O-, -C(CH3)2-, -CHF-, -CHCF3-, -C(O)-, -C(O)O-, -OC(O)-, -C(O)NH-, - C(O)NCH3-, -NHC(O)-, -NCH3C(O)-, cyclopropylene, cyclobutylene, cyclopentylene, cyclohexylidene, oxiranylene, oxetanylene, oxolanylene, oxanilene, azridinylene, azetidinylene, azacyclopentylene, piperidinylidene, piperazin
- L is -(CH2)j-, 1, 2 or 3 methylenes in -(CH2)j- are optionally replaced by a group selected from -O-, -NH-, -NCH3-, -NCH2CH3-, -C(O)-, -C(O)NH-, -NHC(O)-, -NCH3C(O)-, -C(O)NCH3-, azridinylene, azetidinylene, azacyclopentylene, piperidinylidene, piperazinylidene, j is 2, 3, 4, 5, 6, 7, or 8.
- L is -(CH 2 ) j-1 -C(O)-
- the methylene in -(CH 2 ) j-1 -C(O)- is as defined in above L, optionally substituted by one or more groups
- the j is as defined in above L.
- L is selected from
- the L is LA, wherein, in LA,
- the ring D is absent in the LA.
- ring D is a 4-7-membered saturated monocyclic heterocycloalkylene containing 1 or 2 nitrogen heteroatoms, or a 7-11 membered spiro heterocycloalkylene or fused heterocycloalkylene containing 1 or 2 nitrogen heteroatoms.
- the ring D is a 7-11 membered spiro heterocycloalkylene containing one or two nitrogen atoms.
- the ring D is
- ring B is absent in the LA.
- ring B is a 4-7-membered saturated monocyclic heterocycloalkylene containing 1 or 2 nitrogen heteroatoms, or a 7-11 membered spiro heterocycloalkylene or fused heterocycloalkylene containing 1 or 2 nitrogen heteroatoms.
- ring B is a 4-7-membered saturated monocyclic heterocycloalkylene containing one or two nitrogen heteroatoms.
- ring B is piperidylidene, piperazinylidene, or
- ring C is 3-7-membered saturated or partially unsaturated cycloalkylene, 4-11membered saturated or partially unsaturated spirocycloalkylene, 4-11 membered saturated or partially unsaturated fused cycloalkylene, 8-10 membered bicyclic saturated or partially unsaturated cycloalkylene, 4-7 membered saturated or partially unsaturated heterocycloalkylene containing 1-2 heteroatoms independently selected from nitrogen, oxygen or sulfur, 4-11 membered saturated or partially unsaturated spiro heterocycloalkylene containing 1-2 heteroatoms independently selected from nitrogen, oxygen or sulfur, 4-11 membered saturated or partially unsaturated fused heterocycloalkylene containing 1-2 heteroatoms independently selected from nitrogen, oxygen or sulfur, 8-10 membered bicyclic saturated or partially unsaturated heterocycloalkylene containing 1-2 heteroatoms independently selected from nitrogen, oxygen or sulfur.
- ring C is a 4-7-membered saturated monocyclic heterocycloalkylene containing 1 or 2 nitrogen heteroatoms, a 7-11 membered spiro heterocycloalkylene or fused heterocycloalkylene containing 1 or 2 nitrogen heteroatoms.
- ring C is a 4-7-membered saturated monocyclic heterocycloalkylene containing 1 or 2 nitrogen heteroatoms, a 7-11 membered spiro heterocycloalkylene containing 1 or 2 nitrogen heteroatoms.
- the ring C is piperidylidene, piperazinylidene, or
- the ring C is piperidylidene, piperazinylidene,
- X′′′′ is a bond or - C(O)-.
- X′′′′ is -C(O)-.
- L 3 is -(CH 2 ) k , and one methylene in the L 3 is optionally replaced by a group selected from -O-,-NH-,-NCH 3 - or -NCH 2 CH 3 -; k is 1, 2, 3 or 4.
- ring C is 4-7-membered saturated monocyclic heterocycloalkylene containing 1 or 2 nitrogen heteroatoms, or 7-11-membered spiro heterocycloalkylene containing 1 or 2 nitrogen heteroatoms;
- X ⁇ is -C(O)-;
- L 3 is -(CH 2 ) k , one methylene in L3 is optionally replaced by a group selected from -O-, -NH-, -NCH3- or -NCH2CH3-; k is 2, 3 or 4.
- formula L is selected from
- the compound of formula I, and/or a stereoisomer, enantiomer, diastereomer, deuterate, metabolite, hydrate, solvate, prodrug thereof and/or a pharmaceutically acceptable salt thereof is a compound of formula IIa, and/or a stereoisomer, enantiomer, diastereomer, deuterate, metabolite, hydrate, solvate, prodrug thereof and/or a pharmaceutically acceptable salt thereof, wherein the ring A, R a , R b , R c , R d , R e , n are as defined in PTM-71, and the Q 1 , Q 2 , Q 3 , Q 4 , Q 5 , X", Y", m", R 1 ", R 2 " are as defined in ULM-1 herein; the L is as defined herein.
- the compound of formula I, and/or a stereoisomer, enantiomer, diastereomer, deuterate, metabolite, hydrate, solvate, prodrug thereof and/or a pharmaceutically acceptable salt thereof is a compound of formula IIa-1, and/or a stereoisomer, enantiomer, diastereomer, deuterate, metabolite, hydrate, solvate, prodrug thereof and/or a pharmaceutically acceptable salt thereof, wherein the ring A, R a , R b , R c , R d , R e , and n are as defined in PTM-71, the Q 1 , Q 2 , Q 3 , Q 4 , Q 5 , X", Y", m", R 1 ",and R 2 " are as defined in ULM-1 herein; the L3, ring D, ring B, ring C, and X′′′ are as defined herein.
- the compound of formula I has the following structure:
- the invention provides a method for preparing the compound of formula I, formula Ia, formula IA, formula IA-1, formula IA-2, formula IA- 3, formula IB, formula IB-1, formula IC, formula IC-1, formula IC-2, formula IC-3, formula IIa, formula IIa-1, and/or its stereoisomer, enantiomer, diastereomer, deuterate, hydrate, solvate, metabolite, prodrug and/or pharmaceutically acceptable salt.
- the invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a therapeutically effective amount of the compound of formula I, formula Ia, formula IA, formula IA-1, formula IA-2, formula IA-3, formula IB, formula IB-1, formula IC, formula IC-1, formula IC-2, formula IC-3, formula IIa, formula IIa-1, and/or its stereoisomer, enantiomer, diastereomer, deuterate, hydrate, solvate, metabolite, prodrug and/or pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent or excipient.
- the invention provides a method for degrading IRAK4 protein, including a step of contacting the compound of formula I, formula Ia, formula IA, formula IA-1, formula IA-2, formula IA-3, formula IB, formula IB-1, formula IC, formula IC-1, formula IC-2, formula IC-3, formula IIa, formula IIa-1, and/or its stereoisomer, enantiomer, diastereomer, deuterate, hydrate, solvate, metabolite, prodrug and/or pharmaceutically acceptable salt, or its pharmaceutical composition with IRAK4 protein.
- the compound of formula I, formula Ia, formula IA, formula IA-1, formula IA-2, formula IA-3, formula IB, formula IB-1, formula IC, formula IC-1, formula IC-2, formula IC-3, formula IIa, formula IIa-1, and/or its stereoisomer, enantiomer, diastereomer, deuterate, hydrate, solvate, metabolite, prodrug and/or pharmaceutically acceptable salt, or its pharmaceutical composition is used as a drug for the treatment or prevention of IRAK4-mediated diseases or conditions.
- the compound of formula I, formula Ia, formula IA, formula IA-1, formula IA-2, formula IA-3, formula IB, formula IB-1, formula IC, formula IC-1, formula IC-2, formula IC-3, formula IIa, formula IIa-1, and/or its stereoisomer, enantiomer, diastereomer, deuterate, hydrate, solvate, metabolite, prodrug and/or pharmaceutically acceptable salt, or its pharmaceutical composition is used as a drug for the treatment or prevention of diseases or conditions mediated by TLR (other than TLR3R), IL-1 ⁇ or IL-1 ⁇ receptor family (including IL-1R, IL-18R, IL-33R, IL-36R).
- TLR other than TLR3R
- IL-1 ⁇ or IL-1 ⁇ receptor family including IL-1R, IL-18R, IL-33R, IL-36R.
- the compound of formula I, formula Ia, formula IA, formula IA-1, formula IA-2, formula IA-3, formula IB, formula IB-1, formula IC, formula IC-1, formula IC-2, formula IC-3, formula IIa, formula IIa-1, and/or its stereoisomer, enantiomer, diastereomer, deuterate, hydrate, solvate, metabolite, prodrug and/or pharmaceutically acceptable salt, or its pharmaceutical composition is used as a drug for the treatment or prevention of IRAK4-mediated diseases or conditions, which are diseases or conditions driven by MyD88.
- the invention provides a use of the compound of formula I, formula Ia, formula IA, formula IA-1, formula IA-2, formula IA-3, formula IB, formula IB-1, formula IC, formula IC-1, formula IC-2, formula IC-3, formula IIa, formula IIa-1, and/or its stereoisomer, enantiomer, diastereomer, deuterate, hydrate, solvate, metabolite, prodrug and/or pharmaceutically acceptable salt, or its pharmaceutical composition in the preparation of a medicament for the treatment or prevention of IRAK4-mediated diseases or conditions.
- the invention provides a use of the compound of formula I, formula Ia, formula IA, formula IA-1, formula IA-2, formula IA-3, formula IB, formula IB-1, formula IC, formula IC-1, formula IC-2, formula IC-3, formula IIa, formula IIa-1, and/or its stereoisomer, enantiomer, diastereomer, deuterate, hydrate, solvate, metabolite, prodrug and/or pharmaceutically acceptable salt, or its pharmaceutical composition in the preparation of a medicament for the treatment or prevention of diseases or conditions mediated by TLR (other than TLR3R), IL-1 ⁇ , or IL-1 ⁇ receptor family (including IL-1R, IL-18R, IL-33R, IL-36R).
- TLR other than TLR3R
- IL-1 ⁇ IL-18R
- IL-33R IL-1 ⁇ receptor family
- the invention provides a use of the compound of formula I, formula Ia, formula IA, formula IA-1, formula IA-2, formula IA-3, formula IB, formula IB-1, formula IC, formula IC-1, formula IC-2, formula IC-3, formula IIa, formula IIa-1, and/or its stereoisomer, enantiomer, diastereomer, deuterate, hydrate, solvate, metabolite, prodrug and/or pharmaceutically acceptable salt, or its pharmaceutical composition in the preparation of a medicament for the treatment or prevention of a disease or condition regulated by IRAK4, and the IRAK4-mediated disease or condition is a disease or condition driven by MyD88.
- the invention provides a use of the compound of formula I, formula Ia, formula IA, formula IA-1, formula IA-2, formula IA-3, formula IB, formula IB-1, formula IC, formula IC-1, formula IC-2, formula IC-3, formula IIa, formula IIa-1, and/or its stereoisomer, enantiomer, diastereomer, deuterate, hydrate, solvate, metabolite, prodrug and/or pharmaceutically acceptable salt, or its pharmaceutical composition in the preparation of a medicament for the treatment or prevention of cancer, neurodegenerative diseases, viral diseases, autoimmune diseases, inflammatory diseases, hereditary diseases, hormone-related diseases, metabolic diseases, organ transplantation-related diseases, immunodeficiency diseases, destructive bone diseases, proliferative disorders, infectious diseases, conditions related to cell death, thrombin-induced platelet aggregation, liver diseases, pathological immune conditions involving T cell activation, cardiovascular diseases or CNS diseases.
- the invention provides a use of the compound of formula I, formula Ia, formula IA, formula IA-1, formula IA-2, formula IA-3, formula IB, formula IB-1, formula IC, formula IC-1, formula IC-2, formula IC-3, formula IIa, formula IIa-1, and/or its stereoisomer, enantiomer, diastereomer, deuterate, hydrate, solvate, metabolite, prodrug and/or pharmaceutically acceptable salt, or its pharmaceutical composition in the preparation of a medicament for the treatment or prevention of cancer or proliferative disease
- the cancer or proliferative disease is brain cancer, kidney cancer, liver cancer, adrenal cancer, bladder cancer, breast cancer, gastric cancer, ovarian cancer, colon cancer, rectal cancer, prostate cancer, pancreatic cancer, lung cancer, vaginal cancer, cervical cancer, testicular cancer, urogenital cancer, esophageal cancer, laryngeal cancer, skin cancer, bone cancer, thyroid cancer, sarcoma, neuroglioblast
- the invention provides a use of the compound of formula I, formula Ia, formula IA, formula IA-1, formula IA-2, formula IA-3, formula IB, formula IB-1, formula IC, formula IC-1, formula IC-2, formula IC-3, formula IIa, formula IIa-1, and/or its stereoisomer, enantiomer, diastereomer, deuterate, hydrate, solvate, metabolite, prodrug and/or pharmaceutically acceptable salt, or its pharmaceutical composition in the preparation of a medicament for the treatment or prevention of neurodegenerative disease
- the neurodegenerative disease is neurodegenerative disease caused by Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, cerebral ischemia or traumatic injury, glutamate neurotoxicity, hypoxia, epilepsy, diabetes treatment, metabolic syndrome, obesity, organ transplantation or graft-versus-host disease.
- the invention provides a use of the compound of formula I, formula Ia, formula IA, formula IA-1, formula IA-2, formula IA-3, formula IB, formula IB-1, formula IC, formula IC-1, formula IC-2, formula IC-3, formula IIa, formula IIa-1, and/or its stereoisomer, enantiomer, diastereomer, deuterate, hydrate, solvate, metabolite, prodrug and/or pharmaceutically acceptable salt, or its pharmaceutical composition in the preparation of a medicament for the treatment or prevention of inflammatory disease
- the inflammatory disease is eye disease, such as eye allergy, conjunctivitis, dry eye or spring conjunctivitis, diseases affecting the nose, including allergic rhinitis; autoimmune hematological diseases, such as hemolytic anemia, aplastic anemia, pure red blood cell anemia and idiopathic thrombocytopenia, systemic lupus erythematosus, rheumatoid arthritis, polychon
- the invention provides a method for treating or preventing IRAK4-mediated diseases or conditions, including the administraton of a therapeutically effective amount of the compound of formula I, formula Ia, formula IA, formula IA-1, formula IA-2, formula IA-3, formula IB, formula IB-1, formula IC, formula IC-1, formula IC-2, formula IC-3, formula IIa, formula IIa-1, and/or its stereoisomer, enantiomer, diastereomer, deuterate, hydrate, solvate, metabolite, prodrug and/or pharmaceutically acceptable salt, or its pharmaceutical composition to a subject in need thereof.
- the invention provides a method for treating or preventing IRAK4-mediated diseases or conditions, including the administration of a therapeutically effective amount of the compound of formula I, formula Ia, formula IA, formula IA-1, formula IA-2, formula IA-3, formula IB, formula IB-1, formula IC, formula IC-1, formula IC-2, formula IC-3, formula IIa, formula IIa-1, and/or its stereoisomer, enantiomer, diastereomer, deuterate, hydrate, solvate, metabolite, prodrug and/or pharmaceutically acceptable salt, or its pharmaceutical composition to a subject in need thereof, and the IRAK4-mediated disease or condition is a disease or condition driven by MyD88.
- the invention provides a method for the treatment or prevention of diseases or conditions mediated by TLR (other than TLR3R) or IL-1 receptor family (including IL-1R, IL-18R, IL-33R, IL-36R), including the administration of a therapeutically effective amount of the compound of formula I, formula Ia, formula IA, formula IA-1, formula IA-2, formula IA-3, formula IB, formula IB-1, formula IC, formula IC-1, formula IC-2, formula IC-3, formula IIa, formula IIa-1, and/or its stereoisomer, enantiomer, diastereomer, deuterate, hydrate, solvate, metabolite, prodrug and/or pharmaceutically acceptable salt, or its pharmaceutical composition to a subject in need thereof.
- TLR other than TLR3R
- IL-1 receptor family including IL-1R, IL-18R, IL-33R, IL-36R
- the invention provides a preparation method for the compound of formula I, and/or its stereoisomer, enantiomer, diastereomer, deuterate, hydrate, solvate, metabolite, prodrug and/or pharmaceutically acceptable salt,
- Alkyl refers to saturated aliphatic hydrocarbon groups, including linear or branched alkyls; C1-C8 alkyl refers to alkyls containing 1-8 carbon atoms, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-amyl, 1, 1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1, 1, 2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1, 3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl
- Cycloalkyl means saturated or partially unsaturated monocyclic or polycyclic hydrocarbon substituents;
- C3-C12 cycloalkyl means cycloalkyl comprising 3 to 12 carbon atoms;
- C3-C8 cycloalkyl means cycloalkyl comprising 3 to 8 carbon atoms;
- C5-C10 cycloalkyl means cycloalkyl comprising 5 to 10 carbon atoms;
- Non-limiting examples of monocycloalkyl comprise cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cyclohepttrienyl, cyclooctyl, etc., preferably cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl; preferably C3-C8 member
- Polycyclic cycloalkyls include spiro, fused and bridged cycloalkyls.
- “Spiro cycloalkyl” refers to a polycyclic group that shares a carbon atom (called a spiro atom) between monocyclyls. They can contain one or more double bonds, but none of the rings have a fully conjugated ⁇ electronic system. According to the number of spiro atoms shared between the rings, the spiro alkyl is divided into single spiro cycloalkyl, double spiro cycloalkyl or polyspiro cycloalkyl, preferably double spiro cycloalkyl.
- Non-limiting examples of spiro cycloalkyl include:
- fused cycloalkyl refers to a fully carbon polycyclic group in which each ring in the system shares an adjacent pair of carbon atoms with the other rings in the system, wherein one or more rings may contain one or more double bonds, but none of them has a fully conjugated ⁇ -electron system. According to the number of constituent rings, it can be divided into bicyclic, tricyclic, tetracyclic or polycyclic fused cycloalkyl, preferably bicyclic fused cycloalkyl.
- fused cycloalkyl include:
- Bridged cycloalkyl refers to an all-carbon polycyclic group in which any two rings share two carbon atoms that are not directly connected, they can contain one or more double bonds, but no ring has a fully conjugated ⁇ electron system. According to the number of constituent rings, it can be divided into bicyclic, tricyclic, tetracyclic or polycyclic bridged cycloalkyl. Non-limiting examples of bridged cycloalkyl include:
- the cycloalkyl ring may be fused to an aryl, heteroaryl or heterocycloalkyl ring, wherein the ring connected to the parent structure is a cycloalkyl, and non-limiting examples include indanyl, tetrahydronaphthyl, benzocycloheptyl, etc.
- the cycloalkyl may be optionally substituted or unsubstituted.
- Heterocycloalkyl refers to a saturated or partially unsaturated monocyclic or polycyclic hydrocarbon substituent, wherein one or more ring atoms are selected from nitrogen, oxygen, or S(O)r (wherein r is an integer of 0, 1 or 2), but do not contain the ring moieties of -O-O-, -O-S- or -S-S-, and the remaining ring atoms are carbon.
- 3-12-membered heterocycloalkyl refers to a cyclyl containing 3 to 12 ring atoms
- 5-10-membered heterocycloalkyl refers to a cyclyl containing 5 to 10 ring atoms
- 3-8-membered heterocycloalkyl refers to a cyclyl containing 3 to 8 ring atoms, preferably "3-12-membered heterocycloalkyl” containing 1-3 heteroatoms selected from N, O or S, more preferably a 3-12-membered heterocycloalkyl containing 1 or 2 N atoms.
- Non-limiting examples of monocyclic heterocycloalkyl include pyrrolidyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, etc., preferably piperidinyl and piperazinyl.
- Polycyclic heterocycloalkyls include spiro, fused and bridged heterocycloalkyls.
- “Spiro heterocycloalkyl” refers to a polycyclic heterocycloalkyl that shares one atom (called a spiro atom) between single rings, wherein one or more ring atoms are selected from nitrogen, oxygen or S(O)r (wherein r is an integer of 0, 1, 2), and the remaining ring atoms are carbon. They can contain one or more double bonds, but none of the rings have a fully conjugated ⁇ -electron system.
- the spiro cycloalkyl is divided into mono-spiro heterocycloalkyl, bis-spiro heterocycloalkyl or polyspiro heterocycloalkyl, preferably saturated "3-12 membered bis-spiro heterocycloalkyl" containing 1-3 heteroatoms selected from N, O or S; more preferably saturated "3-12 membered bis-spiro heterocycloalkyl" containing 1 or 2 N atoms.
- spiro heterocycloalkyl include:
- “Fused heterocycloalkyl” refers to a polycyclic heterocycloalkyl in which each ring in the system shares an adjacent pair of atoms with other rings in the system, wherein one or more rings may contain one or more double bonds, but none of them has a fully conjugated ⁇ -electron system, wherein one or more ring atoms are selected from nitrogen, oxygen, or S(O)r (wherein r is an integer of 0, 1, 2), the remaining ring atoms are carbon.
- bicyclic, tricyclic, tetracyclic or polycyclic fused heterocycloalkyl preferably "3-12-membered bicyclic fused heterocycloalkyl" containing 1 to 3 heteroatoms selected from N, O or S; more preferably saturated "3-12-membered bicyclic fused heterocycloalkyl" containing 1 or 2 N atoms.
- fused heterocycloalkyl include:
- Bridged heterocycloalkyl refers to a polycyclic heterocycloalkyl in which any two rings share two atoms that are not directly connected. They can contain one or more double bonds, but no ring has a fully conjugated ⁇ electron system, wherein one or more ring atoms are selected from nitrogen, oxygen or S(O)r (wherein r is an integer of 0, 1, 2), and the remaining ring atoms are carbon. According to the number of constituent rings, it can be divided into bicyclic, tricyclic, tetracyclic or polycyclic bridged cycloalkyl.
- the non-limiting examples of bridged heterocycloalkyl include:
- the heterocycloalkyl ring can be fused to the aryl, heteroaryl or cycloalkyl, wherein the ring connected with the parent structure is heterocycloalkyl, non-limiting examples include: the heterocycloalkyl may be optionally substituted or unsubstituted.
- Aryl refers to all-carbon monocyclyls or fused polycyclyls (that is, rings sharing adjacent pairs of carbon atoms) and polycyclyls having conjugated ⁇ -electron systems
- 6-10-membered aryl refers to all-carbon aryls containing 6-10 carbons, such as phenyl and naphthyl; preferably phenyl.
- the aryl ring may be fused to the heteroaryl, heterocycloalkyl or cycloalkyl, wherein the ring connected with the parent structure is an aryl ring, and the non-limiting examples include: the aryl may be optionally substituted or unsubstituted.
- Heteroaryl refers to a heteroaromatic system comprising 1 to 4 heteroatoms, the heteroatoms include nitrogen, oxygen or S(O)r (wherein r is an integer of 0, 1, 2), 5-6-membered heteroaryl refers to a heteroaromatic system containing 5 to 6 ring atoms, and 5-10-membered heteroaryl refers to a heteroaromatic system containing 5 to 10 ring atoms, preferably 5-6-membered heteroaryl; more preferably a 5-6-membered heteroaryl containing 1 or 2 N atoms; non-limiting examples include furyl, thienyl, pyridyl, pyrrolyl, N-alkylpyrrolyl, pyrimidyl, pyrazinyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, etc.; preferably pyridyl.
- the heteroaryl ring may be fused to the aryl, heterocycloalkyl or cycloalkyl, wherein the ring connected with the parent structure is a heteroaryl, and the non-limiting examples include: the heteroaryl may be optionally substituted or unsubstituted.
- Alkenyl means an alkyl as defined above consisting of at least two carbon atoms and at least one carbon-carbon double bond
- C2-8 alkenyl means a linear or branched alkenyl containing 2-8 carbons, including but not limited to vinyl, 1-propenyl, 2-propenyl, 1-, 2- or 3-butenyl, etc., preferably "C2-6 alkenyl", more preferably "C2-4 alkenyl”.
- the alkenyl may be substituted or unsubstituted.
- Alkynyl refers to an alkyl as defined above consisting of at least two carbon atoms and at least one carbon-carbon triple bond
- C2-8 alkynyl refers to a linear or branched alkynyl containing 2-8 carbons, including but not limited to ethynyl, 1-propynyl, 2-propynyl, 1-, 2- or 3-butynyl, preferably "C2-6 alkynyl", more preferably "C2-4 alkynyl”.
- the alkynyl may be substituted or unsubstituted.
- Subgroup refers to a divalent, such as alkylene refers to divalent alkyl, alkenylene refers to divalent alkenyl, alkynylene refers to divalent alkynyl, cycloalkylene to divalent cycloalkyl, heterocycloalkylene to divalent heterocycloalkyl, arylene to divalent aryl, heteroarylene to divalent heteroaryl, and the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl as defined above, the subgroups may be optionally substituted or unsubstituted.
- Alkoxy refers to -O-(alkyl), wherein the alkyl is as defined above.
- C1-C8 alkoxy refers to an alkyloxy containing 1 to 8 carbons. Non-limiting examples include methoxy, ethoxy, propoxy, butoxy, etc. The alkoxy may be optionally substituted or unsubstituted.
- Cycloalkoxy refers to -O-(unsubstituted cycloalkyl), wherein the cycloalkyl is as defined above.
- C3-C8 cycloalkoxy refers to cycloalkyloxys containing 3 to 8 carbons. Non-limiting examples include cyclopropoxy, cyclobutoxy, cyclopentoxy, cyclohexoxy, etc.
- the cycloalkoxy may be optionally substituted or unsubstituted.
- Haloalkyl refers to an alkyl substituted by one or more fluorine, chlorine, bromine or iodine atoms, wherein the alkyl is as defined above, and non-limiting examples include difluoromethyl, dichloromethyl, dibromomethyl, trifluoromethyl, trichloromethyl, tribromomethyl, etc.
- Haloalkoxy refers to a group in which hydrogen on an alkyl is substituted by one or more fluorine, chlorine, bromine or iodine atoms, wherein the alkoxy is as defined above.
- alkoxy is as defined above.
- Hydroxyalkyl refers to an alkyl optionally substituted by one or more -OH, wherein the alkyl is as defined above, and non-limiting examples include hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxyisopropyl.
- Aminoalkyl refers to an alkyl optionally substituted by one or more -NH 2 , wherein the alkyl is as defined above, and non-limiting examples include aminomethyl, aminoethyl, aminopropyl, aminoisopropyl.
- Ammonia and “amine” are recognized in the art and refer to substituted or unsubstituted ammonia.
- Carboxyl or “carboxylic acid” refers to -COOH.
- Halogen refers to fluorine, chlorine, bromine or iodine.
- Cyano refers to -CN.
- Hydrophill refers to -OH.
- Raney-Ni refers to Raney nickel (hydrogen active catalytic reducing agent).
- Des-martin refers to 1,1,1-triacetoxy-1,1-dihydro-1,2-benziodoxol-3-(1H)-one.
- PdCl 2 (dppf) refers to [1,1-bis (diphenylphosphorus) ferrocene] palladium dichloride.
- T3P refers to 2,4, 6-tripropyl-1,3,5,2,4,6-trioxytriphosphate-2,4,6-trioxide.
- HATU refers to 2-(7-azabenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate.
- DPBS Dulbecco's phosphate buffer saline
- PBS refers to phosphate buffer saline
- SDS-PAGE refers to sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
- PVDF polyvinylidene fluoride
- Optional means that a subsequently described event or environment may, but does not have to, occur, and that description includes the place where the event or environment occurs or does not occur.
- a heterocycloalkyl optionally substituted by an alkyl means that an alkyl may, but does not have to be present, and the description includes the case where the heterocycloalkyl is substituted by an alkyl and the case where the heterocycloalkyl is not substituted by an alkyl.
- Substituted means that one or more hydrogen atoms, preferably at most 5, more preferably 1 to 3 hydrogen atoms are substituted independently of each other by a corresponding number of substituents. It goes without saying that the substituents are only in their possible chemical positions, and those skilled in the art can determine (experimentally or theoretically) possible or impossible substitutions without too much effort. For example, amino or hydroxyls with free hydrogen may be unstable when combined with carbon atoms with unsaturated (e. g. olefinic) bonds.
- “Pharmaceutical composition” means a mixture comprising one or more compounds described herein or their physiologically/pharmaceutically acceptable salts or prodrugs with other chemical components, as well as other components such as physiologically/pharmaceutically acceptable carriers and excipients.
- the purpose of the pharmaceutical composition is to promote the administration of organisms, facilitate the absorption of active ingredients and thus exert biological activity.
- the present invention also provides pharmaceutically acceptable salts of compounds of formula (I).
- pharmaceutically acceptable salt refers to an acid addition salt or a base addition salt of a compound of the present invention that is relatively non-toxic.
- the acid addition salts are salts of the compounds of formula (I) of the present invention and suitable inorganic or organic acids, these salts can be prepared during the final separation and purification of the compounds, or can be prepared by reacting the purified compounds of formula (I) in their free base form with suitable organic or inorganic acids.
- Representative acid addition salts include hydrobromate, hydrochloride, sulfate, bisulfate, sulfite, acetate, oxalate, valerate, oleate, palmitic acid, stearate, lauroleate, borate, benzoate, lactate, phosphate, hydrophosphate, carbonate, bicarbonate, toluate, citrate, maleate, fumarate, succinate, tartrate, benzoate, mesylate, p-toluene sulfonate, gluconate, lactobionate and lauryl sulfonate, etc.
- the base addition salt is a salt formed by a compound of formula (I) and a suitable inorganic or organic base, including, for example, a salt formed with alkali metals, alkaline earth metals, and quaternary ammonium cations, such as sodium salt, lithium salt, potassium salt, calcium salt, magnesium salt, tetramethylquaternary ammonium salt, tetraethyl quaternary ammonium salt, etc.; amine salt includes salts formed with ammonia (NH 3 ), primary amine, secondary amine or tertiary amine, such as methylamine salt, dimethylamine salt, trimethylamine salt, triethylamine salt, ethylamine salt, etc.
- a salt formed with alkali metals, alkaline earth metals, and quaternary ammonium cations such as sodium salt, lithium salt, potassium salt, calcium salt, magnesium salt, tetramethylquaternary ammonium salt, tetraethyl quaternary
- the compounds of the invention can be administered to mammals, including humans, orally, rectally, parenterally (intravenous, intramuscular or subcutaneous), topically (powder, ointment or drops), or intratumorally.
- the dosage of the compound of the present invention may be about 0.05-300mg/kg body weight/day, preferably 10-300mg/kg body weight/day, more preferably 10-150mg/kg body weight/day.
- the compounds of the present invention may be formulated as solid dosage forms for oral administration, including, but not limited to, capsules, tablets, pills, powders, granules, and the like.
- the active ingredient i.e.
- the compound of formula (I) of the present invention is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or mixed with any of the following components: (1) fillers or compatibilizer, for example, starch, lactose, sucrose, glucose, mannitol and silicic acid, etc.; (2) binders, for example, hydroxymethyl cellulose, alginate, gelatin, polyvinylpyrrolidone, sucrose and arabic gum, etc.; (3) humectants, for example, glycerol, etc; (4) disintegrating agents, for example, agar, calcium carbonate, potato starch or tapioca starch, alginic acid, certain composite silicates, and sodium carbonate, etc; (5) dissolution-retarding agents, for example, paraffin, etc; (6) absorption accelerators, for example, quaternary ammonium compounds, etc; (7) wetting agents, for example, cetyl alcohol and glyceryl mono
- the solid dosage forms such as tablets, sugar pills, capsules, pills and granules can be coated or microencapsulated with coating and shell materials such as enteric coatings and other materials known in the art. They may contain opaque agents, and the release of the active ingredient in such a composition may be released in a delayed manner in a part of the digestive tract. Examples of embedding components that can be employed are polymeric materials and waxy materials. If necessary, the active ingredient may also form a microcapsule form with one or more of the excipients described above.
- liquid dosage forms for oral administration, including, but not limited to, pharmaceutically acceptable emulsions, solutions, suspensions, syrups, tinctures, and the like.
- liquid dosage forms may contain inert diluents such as water and other solvents, solubilizers and emulsifiers, such as ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butanediol, dimethylformamide, and oils, especially cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil or a mixture of these substances as conventionally used in the art.
- the liquid dosage forms of the present invention may also contain conventional auxiliaries such as wetting agents, emulsifiers and suspending agents, sweet
- the suspending agent includes, for example, ethoxylated isooctadecanol, polyoxyethylene sorbitol and dehydrated sorbitol esters, microcrystalline cellulose, aluminum methanol and agar, or a mixture of these substances.
- the compounds of the present invention, or pharmaceutically acceptable salts thereof may be formulated as dosage forms for parenteral injection including, but not limited to, physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powders for re-dissolution into sterile injectable solutions or dispersions.
- Suitable carriers, diluents, solvents or excipients include water, ethanol, polyols and suitable mixtures thereof.
- the compounds of the present invention, or pharmaceutically acceptable salts thereof may also be formulated as dosage forms for topical administration, including, for example, ointments, powders, suppositories, drops, propellants, inhalants, and the like.
- the compounds of formula (I) of the invention, or pharmaceutically acceptable salts thereof, as active ingredient are mixed with a physiologically acceptable carrier and optionally a preservative, a buffer, or, if necessary, a propellant as may be required under sterile conditions.
- the present invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound of formula (I) of the present invention or a pharmaceutically acceptable salt thereof as active ingredient, and a pharmaceutically acceptable carrier, excipient or diluent.
- a compound of formula (I) or a pharmaceutically acceptable salt thereof is usually mixed with a pharmaceutically acceptable carrier, excipient or diluent.
- composition of the present invention can be formulated as a conventional pharmaceutical preparation according to the conventional preparation method.
- a conventional pharmaceutical preparation for example, tablets, pills, capsules, powders, granules, emulsions, suspensions, dispersions, solutions, syrups, elixirs, ointments, drops, suppositories, inhalants, propellants, etc.
- the compound of the present invention or its pharmaceutically acceptable salt may be administered alone, or (if necessary) in combination with other pharmaceutically acceptable therapeutic agents, such as in combination with other anti-tumor drugs, anti-inflammatory drugs or autoimmune drugs.
- the ingredients to be combined may be administered simultaneously or sequentially, in the form of a single formulation or in the form of a different formulation.
- the combination may include not only a combination of a compound of the present invention and one other active agent, but also a combination of a compound of the present invention and two or more other active agents.
- the present invention proves that the compound of formula I of the present invention can effectively bind to the IRAK4 target protein or produce an inhibitory effect through the IRAK4 kinase activity test experiment, and the compound of formula I of the present invention can effectively and specifically degrade the IRAK4 protein in THP-1 cells by Western-Blot.
- the compound of formula I of the present invention can effectively inhibit the production of IL-6 by immune cells, and the compound of the present invention has good degradation selectivity, and the compound of formula I of the present invention, and/or its stereoisomers, enantiomers, diastereomers, deuterates, hydrates, solvates, metabolites, prodrugs and/or pharmaceutically acceptable salts can effectively and selectively degrade IRAK4 protein, so as to achieve the effect of preventing or treating diseases or conditions related to IRAK4.
- Nitric acid (1.0mL,65%) was added dropwise to a solution of 2-fluoro-4-(trifluoromethoxy) benzaldehyde (1.0g,4.8mmol) in sulfuric acid (5ml) while keeping the temperature below -10°C. After dripping, the solution was poured into ice water (20mL) and stirred for 10 minutes. Filtered, solid was washed with water (10mL ⁇ 3), and dried under reduced pressure to obtain 0.9g of crude target product. The crude product can be used for the next step without further purification.
- Step 2 Preparation of tert-butyl 4-(6-methoxy-5-nitro-2H-indazol-2-yl) piperidine-1-carboxylate
- Step 3 Preparation of tert-butyl 4-(5-amino-6-methoxy-2H-indazol-2-yl) piperidine-1-carboxylate
- Iron powder (2.85g,50.9mmol) and ammonium chloride (0.13g,2.3mmol) were added to a solution of tert-butyl 4-(6-methoxy-5-nitro-2H-indazol-2-yl) piperidin-1-carboxylate (1.7g,4.5mmol) in ethanol (20ml), and the reaction solution was reacted at 90 °C for 2 hours. After the reaction solution was cooled to room temperature, it was filtered and concentrated to obtain 2.01g of crude target product, which was directly used for the next reaction.
- Step 4 Preparation of tert-butyl 4-(6-methoxy-5-(6-(trifluoromethyl) pyridine-2-amido)-2H-indazol-2-yl) piperidine-1-carboxylate
- 6-(Trifluoromethyl) pyridine-2-carboxylic acid (940mg,4.9mmol) and N,N-diisopropylethylamine (1.9g,14.7mmol) were added to a solution of tert-butyl 4-(5-amino-6-methoxy-2H-indazol-2-yl) piperidine -1-carboxylate (1.7g,4.9mmol) in tetrahydrofuran, then T 3 P (1.5g) was added, and the reaction solution was stirred for 2 hours at room temperature.
- Step 5 Preparation of N-(6-methoxy-2-(piperidin-4-yl)-2H-indazol-5-yl)-6-(trifluoromethyl) pyridinecarboxamide
- Trifluoroacetic acid (1ml) was added to a solution of tert-butyl 4-(6-methoxy-5-(6-(trifluoromethyl) pyridine-2-amido)-2H-indazol-2-yl) piperidine-1-carboxylate (435 mg,0.795 mmol) in dichloromethane.
- the reaction solution was stirred at room temperature for 1h.
- the solvent was removed by concentration under reduced pressure to obtain the target crude product (500mg). The crude product was used directly for the next step.
- Step 2 Preparation of methyl 2-(1-(tert-butoxycarbonyl) piperidin-4-yl)-5-nitro-2H-indazole-6-carboxylate
- Step 3 Preparation of methyl 5-amino-2-(1-(tert-butoxycarbonyl) piperidin-4-yl)-2H-indazole-6-carboxylate
- Iron powder (2.85g,50.9mmol) and ammonium chloride (0.13g,2.3mmol) were added to a solution of methyl 2-(1-(tert-butoxycarbonyl) piperidin-4-yl)-5-nitro-2H-indazole-6-carboxylate (1.7g,4.5 mmol) in ethanol (20 ml).
- the reaction solution was stirred at 90°C for 2h.
- the reaction solution was cooled to room temperature, filtered, and the filtrate was concentrated under reduced pressure to obtain 2.01g of the crude target product as an oil.
- the crude product was used directly for the next step.
- Step 4 methyl 2-(1-(tert-butoxycarbonyl) piperidin-4-yl)-5-(6-(trifluoromethyl) pyridine carboxamide)-2H-indazole-6-carboxylate
- T 3 P(650 mg) was added to a mixture of methyl 5-amino -2-(1-(tert-butoxycarbonyl) piperidin-4-yl)-2H-indazole-6-carboxylate (170 mg,0.45 mmol), 6-(trifluoromethyl) pyridine-2-carboxylic acid (86.8mg,0.45 mmol) and N,N-diisopropylethylamine(88 mg, 0.68 mmol) in tetrahydrofuran.
- the reaction solution was stirred at room temperature for 2 hours. The solvent was removed by concentration under reduced pressure. Water (20mL) and ethyl acetate (20mL) were added.
- the water layer was separated and extracted with ethyl acetate (20ml ⁇ 2).
- the organic layers were combined, washed with saline (20mL ⁇ 2), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure.
- the concentrate was purified by column chromatography to obtain 150mg of target product as a yellow solid.
- Step 5 Preparation of tert-butyl 4-(6-(2-hydroxyprop-2-yl)-5-(6-(trifluoromethyl) pyridinecarboxamido)-2H-indazol-2-yl) piperidine-1-carboxylate
- Lithium chloride (192mg,4.57mmol) was added to a solution of methyl 2-(1-(tert-butoxycarbonyl) piperidin-4-yl)-5-(6-(trifluoromethyl) pyridinecarboxamido)-2H-indazole-6-carboxylate (500 mg,0.91 mmol) in tetrahydrofuran.
- the reaction solution was cooled to 0°C, and then tetrahydrofuran methylmagnesium bromide (3.04ml,1M) was added.
- the reaction solution was stirred at room temperature for 12h, quenched with ammonium chloride aqueous solution, and water (30mL) and ethyl acetate (50mL) were added.
- the water layers were separated and extracted with ethyl acetate (50ml ⁇ 2), the organic layers were combined, washed with saline (50ml ⁇ 2), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure, and the concentrate was purified by column chromatography to obtain 435 mg of target product as a white solid.
- Step 6 Preparation of N-(6-(2-hydroxyprop-2-yl)-2-(piperidin-4-yl)-2H-indazol-5-yl)-6-(trifluoromethyl) pyridinecarboxamide
- Step 2 methyl 5-(6-(trifluoromethyl) pyridine carboxamide)-1H-indazole-6-carboxylate
- N,N-diisopropylethylamine(4.5g, 0.0345 mol) was added to a solution of methyl 5-amino-1H-indazole-6-carboxylate (4.4g,0.023 mol) and 6-(trifluoromethyl) picolinic acid (4.4g,0.023 mol) in tetrahydrofuran (50 ml), the mixture was cooled to 0 °C, and then T3P(18.0g, 0.0345 mol) was added in batches, and the reaction mixture was stirred at room temperature for 2 hours.
- the solvent was removed by concentration under reduced pressure, water (50ml) and ethyl acetate (100ml) were added, and the water layer was separated and extracted with ethyl acetate (100ml ⁇ 2).
- the organic layer was collected, washed with saturated saline (100mL ⁇ 2), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure.
- the concentrate was purified by column chromatography to obtain 7.87g of target product as a yellow solid.
- Step 3 N-(6-(2-hydroxyprop-2-yl)-1H-indazol-5-yl)-6-(trifluoromethyl) pyridine carboxamide
- the water layer was separated and extracted with ethyl acetate (100ml ⁇ 2).
- the organic layer was collected, washed with saturated salt water (100mL ⁇ 2), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure.
- the concentrate was purified by column chromatography to obtain 532mg of target product as a yellow solid.
- Step 1 Preparation of 3-(2,4-dioxotetrahydropyrimidin-1 (2 H )-yl)-4-methoxybenzoic acid
- 3-Amino-4-methoxybenzoic acid (5.0g,2.93mmol) was suspended in acrylic acid (8.05mL,117mmol) and stirred at 100 °C for 3 h, then the reaction solution was stirred and cooled to room temperature.
- Acetic acid 33ml was added, the stirred suspension was heated at 100 °C for 10 minutes, urea (11.00g, 183mmol) was added, and the reaction solution was stirred at 120 °C overnight.
- the reaction solution was added to a mixture of ice water and concentrated hydrochloric acid (37%), stirred, and the obtained suspension was stored overnight in a refrigerator at 5°C, then filtered, and the solid was washed with water and dried to obtain the solid.
- the solid was ground in hydrochloric acid solution (0.05M), filtered, washed with methyl tert-butyl ether, and dried under reduced pressure at 40 °C to obtain 6.29g of target product.
- Benzyl alcohol (109.6g,1.01mol) was added to a solution of sodium hydride (60% mineral oil mixture, 54.0g,1.35mol) in N,N-dimethylformamide (600mL) at 0 °C. After stirring for 30 minutes, 2,6-dichloropyridine (50.0g,0.338mol) was added. The reaction mixture was heated to 80°C and stirred overnight, and after cooling to room temperature, the reaction mixture was quenched with ice water (1000mL). The solid was filtered and dried to obtain 75.9g of target product.
- N-bromosuccinimide(41.7g,0.23mol) was added to a solution of 2,6-bis (benzyloxy) pyridine (75.9g,0.26mol) in acetonitrile (600mL). The reaction mixture was stirred at 80°C for 2 hours. After the reaction was completed, the reaction mixture was concentrated under reduced pressure. The concentrate was diluted with ethyl acetate (500mL) and washed with water and saturated saline. The organic layer was collected and dried over anhydrous sodium sulfate, filtered and concentrated. The concentrate was purified by column chromatography to obtain 75.0g of target product.
- PdCl 2 (dppf)-chloroform complex (612 mg,0.84 mmol) and sodium carbonate (1.77g,16.74 mmol) were added to a mixture of 2, 6-bis (benzyloxy)-3-bromopyridine (3.1g,8.37 mmol) and 3-boro-4-fluorobenzoic acid (1.85g,10.05 mmol) in dioxane (31 mL) and water (7.5 mL). The reaction mixture was heated to 90°C under nitrogen protection and the reaction was maintained for 16 hours.
- step 4 Preparation of 3-(2, 6-dioxopiperidin-3-yl)-4-fluorobenzoic acid
- Step 1 Preparation of tert-butyl 9-(3-(2, 4-dioxotetrahydropyrimidin-1 (2H)-yl)-4-methoxybenzoyl)-3, 9-diazaspiro[5.5] undecyl-3-carboxylate
- HATU(1.66g,4.37 mmol), tert-butyl 3, 9-diazaspiro[5.5] undecyl-3-carboxylate (0.96g,3.78 mmol) and N-methylmorpholine(0.8g,7.92 mmol) were added to a solution of 3-(2, 4-dioxotetrahydropyrimidin-1(2H)-yl)-4-methoxybenzoic acid (1.0g,3.78 mmol) in N,N-dimethylformamide (10 mL). After stirring for 2h, the reaction mixture was quenched with water (50mL) and extracted with ethyl acetate (3 ⁇ 50mL). The organic layer was collected and washed with saturated saline (3 ⁇ 50mL), dried over anhydrous sodium sulfate, filtered and concentrated. The concentrate was purified by column chromatography to obtain 1.55g of target product as a white solid.
- Step 2 Preparation of 1-(2-methoxy-5-(3, 9-diazaspiro [5.5] undecyl-3-carbonyl) phenyl) dihydropyrimidine-2,4 (1H,3H)-dione
- Step 1 Preparation of 1-(5-(9-(2, 2-dimethoxyethyl)-3, 9-diazaspiro[5.5]undecyl-3-carbonyl)-2-methoxyphenyl) dihydropyrimidine -2,4(1H,3H)-dione
- Step 2 Preparation of 2-(9-(3-(2, 4-dioxotetrahydropyrimidin-1 (2H)-yl)-4-methoxybenzoyl)-3, 9-diazaspiro [5.5] undec-3-yl) acetaldehyde
- Step 1 Preparation of 1-(5-(9-(3-(1, 3-dioxan-2-yl) propyl)-3, 9-diazaspiro[5.5] undecyl-3-carbonyl)-2-methoxyphenyl) dihydropyrimidine-2, 4( 1H,3H)-dione
- Step 2 Preparation of 4-(9-(3-(2, 4-dioxotetrahydropyrimidin-1 (2H)-yl)-4-methoxybenzoyl)-3, 9-diazaspiro [5.5] undec-3-yl) butyraldehyde
- Step 1 Preparation of tert-butyl (5-((tetrahydro-2H-pyran-2-yl) oxy) pentyl) carbamate
- Step 2 Preparation of tert-butyl methyl (5-((tetrahydro-2H-pyran-2-yl) oxy) pentyl) carbamate
- the mixture was extracted with ethyl acetate (2 ⁇ 20mL), organic layers were combined, and washed with 10mL of water and 20mL of saturated brine. The mixture was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The concentrate was purified by column chromatography to obtain 100 mg of the target product.
- Step 5 Preparation of 3-(2,4-dioxotetrahydropyrimidin-1 (2H)-yl)-4-methoxy-N-methyl-N-(5-oxopentyl) benzamide
- the mixture was extracted with dichloromethane (2 ⁇ 20mL), organic layers were combined and washed with 20mL saturated saline. The organic layer was collected and dried over anhydrous sodium sulfate, then concentrated under reduced pressure to obtain 110.0mg of the target crude product.
- Trifluoroacetic acid (1.5mL) was added to a solution of tert-butyl 4-(2-oxoethyl) piperidin-1-carboxylate (580mg,2.72mol) in dichloromethane (10mL). The reaction solution was stirred at room temperature for 2 hours. The reactants were concentrated under reduced pressure to obtain 320mg of oil, which was directly used in the next reaction.
- Step 2 Preparation of 2-(1-(3-(2, 4-dioxotetrahydropyrimidin-1 (2H)-yl)-4-methoxybenzoyl) piperidin-4-yl) acetaldehyde
- Triethylamine (406mg,3.98mmol) and HATU(605mg,1.59mmol) were added to a mixture of 2-(piperidin-4-yl) acetaldehyde (320 mg,1.33 mmol) and 3-(2, 4-dioxotetrahydropyrimidin-1 (2H)-yl)-4-methoxybenzoic acid (150 mg,1.33 mmol) in N,N-dimethylformamide (5mL). The reaction solution was stirred at room temperature for 12 hours.
- the reaction solution was poured into water (50mL), extracted with ethyl acetate (50mL ⁇ 2), and the organic layer was collected, washed with saline (50mL ⁇ 2), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure.
- the concentrate was purified by column to obtain 120 mg of target product as a yellow solid.
- Step 1 Preparation of tert-butyl 4-(3-(2, 4-dioxotetrahydropyrimidin-1 (2H)-yl)-4-methoxybenzoyl) piperazine-1-carboxylate
- N,N-diisopropylethylamine(440mg,9.3mmol) and HATU(520mg, 1.36mmol) were added to a mixture of 3-(2, 4-dioxotetrahydropyrimidin-1 (2H)-yl)-4-methoxybenzoic acid (300 mg,1.14 mmol) and tert-butyl piperazine-1-carboxylate (212 mg,1.14 mmol) in N,N-dimethylformamide (10mL).
- the reaction solution was stirred at room temperature for 2h, then the reaction solution was poured into water (20mL) and extracted with ethyl acetate (20mL ⁇ 2). The organic layers were combined, washed with saline (20mL ⁇ 2), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure.
- the concentrate was purified by column to obtain 400mg of target product as a yellow solid.
- Step 2 Preparation of 1-(2-methoxy-5-(piperazin-1-carbonyl) phenyl) dihydropyrimidine-2,4(1H,3H)-dione
- Trifluoroacetic acid (1.5mL) was added to a solution of tert-butyl 4-(3-(2, 4-dioxotetrahydropyrimidin-1 (2H)-yl)-4-methoxybenzoyl) piperazine-1-carboxylate (400 mg,0.93 mmol) in dichloromethane (10 mL).
- the reaction solution was stirred at room temperature for 2 hours.
- the solution was concentrated under reduced pressure to obtain 300mg of crude target product as an oil. The crude product was used directly for the next step.
- Step 3 Preparation of 1-(5-(4-(2, 2-dimethoxyethyl) piperazin-1-carbonyl)-2-methoxyphenyl) dihydropyrimidine-2,4 (1H,3H)-dione
- Potassium carbonate (371 mg, 2.71 mmol) and potassium iodide (15 mg,0.01 mmol) were added to a mixture of 1-(2-methoxy-5-(piperazin-1-carbonyl) phenyl) dihydropyrimidine-2,4(1H,3H)-dione (300 mg,0.9 mmol) and 2-bromo-1, 1-dimethoxyethane (305 mg,1.81 mmol) in acetone (20 mL).
- the reaction solution was stirred at 80°C for 12h.
- the reaction solution was concentrated under reduced pressure to remove the solvent, and water (10mL) and ethyl acetate (10mL) were added.
- the water layers were separated and extracted with ethyl acetate (10mL ⁇ 2), and the organic layers were combined, washed with saline (10mL ⁇ 2), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure.
- the concentrate was purified by column to obtain 120 mg of target product as an oil.
- Step 4 Preparation of 2-(4-(3-(2, 4-dioxotetrahydropyrimidin-1 (2H)-yl)-4-methoxybenzoyl) piperazin-1-yl) acetaldehyde
- Trifluoroacetic acid (6mL) was added to a solution of 1-(5-(4-(2, 2-dimethoxyethyl) piperazin-1-carbonyl)-2-methoxyphenyl) dihydropyrimidine-2,4 (1H,3H)-dione (120 mg,0.27 mmol) in dichloromethane (10mL). The reaction solution was stirred at room temperature for 12h. The solvent was removed by concentration under reduced pressure to obtain 53mg of the crude target product. The crude product was used directly for the next step.
- Step 1 Preparation of 3-(2, 4-dioxotetrahydropyrimidin-1 (2H)-yl)-N-(2-(2-(2-(2-(2-(2-hydroxyethoxy) ethoxy) ethyl)-4-methoxybenzamide
- Step 2 Preparation of 3-(2, 4-dioxotetrahydropyrimidin-1 (2H)-yl)-4-methoxy-N-(2-(2-(2-oxoethoxy) ethoxy) ethyl) benzamide
- Step 1 Preparation of tert-butyl (5-(4-(6-methoxy-5-(6-(trifluoromethyl) pyridinecarboxamido)-2H-indazol-2-yl) piperidin-1-yl) pentyl) carbamate
- Step 2 Preparation of N-(2-(1-(5-aminopentyl) piperidin-4-yl)-6-methoxy-2H-indazol-5-yl)-6-(trifluoromethyl) pyridinecarboxamide
- Step 1 Preparation of tert-butyl (2-(2-(4-(6-methoxy-5-(6-(trifluoromethyl) pyridinecarboxamido)-2H-indazol-2-yl) piperidin-1-yl) ethoxy) ethyl) carbamate
- the resulting reaction solution was diluted with ethyl acetate (50mL), the organic phase was collected, washed with water (2 ⁇ 50mL) and brine (50mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure.
- the concentrate was purified by column chromatography to obtain 330 mg of yellow oily product.
- Step 2 Preparation of N-(2-(1-(2-(2-aminoethoxy) ethyl) piperidin-4-yl)-6-methoxy-2H-indazol-5-yl)-6-(trifluoromethyl) pyridinecarboxamide
- Step 1 Preparation of tert-butyl 4-(2-(4-(6-methoxy-5-(6-(trifluoromethyl) pyridinecarboxamido)-2H-indazol-2-yl) piperidin-1-yl) ethyl) piperidine-1-formate
- the reaction solution was diluted with ethyl acetate (50mL), washed with water (2 ⁇ 50mL) and saturated saline (50mL), and the organic phase was collected, dried over anhydrous sodium sulfate, and concentrated under reduced pressure.
- the concentrate was purified by column chromatography to obtain 700 mg of target product as a yellow solid.
- Step 2 Preparation of N-(6-methoxy-2-(1-(2-(piperidin-4-yl) ethyl) piperidin-4-yl)-2H-indazol-5-yl)-6-(trifluoromethyl) pyridinecarboxamide
- Step 1 Preparation of N-(2-(1-(2, 2-dimethoxyethyl) piperidin-4-yl)-6-methoxy-2H-indazol-5-yl)-6-(trifluoromethyl) pyridinecarboxamide
- Potassium carbonate (1.235g, 8.95 mmol) and potassium iodide (149mg,0.89 mmol) were added to a mixture of N-(6-methoxy-2-(piperidin-4-yl)-2H-indazol-5-yl)-6-(trifluoromethyl) pyridinecarboxamide (750 mg,1.79 mmol) and 2-bromo-1,1-dimethoxyethane (46mg,0.3 mmol) in acetonitrile (20 mL). The reaction solution was stirred at 80°C for reaction overnight.
- the reaction solution was concentrated under reduced pressure to remove the solvent, water (20mL) was added, extracted with ethyl acetate (20mL ⁇ 3), and the organic layers were combined, washed with saturated saline (50mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure.
- the concentrate was purified by column to obtain 500 mg of target product as an oil.
- Step 2 Preparation of N-(6-methoxy-2-(1-(2-oxoethyl) piperidin-4-yl)-2H-indazol-5-yl)-6-(trifluoromethyl) pyridinecarboxamide
- step 1 tert-butyl 4-(3-(p-toluenesulfonyloxy) propyl) piperidine-1-formate
- Triethylamine (2.1g,20.6 mmol) and p-toluenesulfonyl chloride(1.2g,6.1 mmol) were added to a stirred solution of tert-butyl 4-(3-hydroxypropyl) piperidine-1-formate (1.0g,4.1 mmol) in dichloromethane (30 mL). After the reaction mixture was stirred at 25°C overnight, the reaction was quenched with saturated ammonium chloride (50mL) and extracted with dichloromethane (2 ⁇ 50mL). The organic layer was collected and concentrated under reduced pressure. The concentrate was purified by column chromatography to obtain 1.1g of target product.
- Step 2 tert-butyl 4-(3-(4-(6-methoxy-5-(6-(trifluoromethyl) pyridinecarboxamido))-2H-indazol-2-yl) piperidin-1-yl) propyl) piperidine-1-formate
- N-(6-methoxy-2-(piperidin-4-yl)-2H-indazol-5-yl)-6-(trifluoromethyl) pyridinecarboxamide (1.2g,2.9 mmol) and potassium carbonate (2.0g,14.5 mmol) were added to a stirred solution of tert-butyl 4-(3-(p-toluenesulfonyloxy) propyl) piperidine-1-formate (1.1g,2.9 mmol) in N,N-dimethylformamide(15mL).
- the reaction mixture was stirred at 75°C for 3 hours.
- the reaction was quenched with water (100mL) and extracted with ethyl acetate (3 ⁇ 50mL).
- the organic layer was collected and washed with saturated saline (100mL) and concentrated under reduced pressure.
- the concentrate was purified by column chromatography to obtain 1.2 g of target product.
- Step 3 N-(6-methoxy-2-(1-(3-piperidin-4-yl) propyl) piperidin-4-yl)-2H-indazol-5-yl)-6-(trifluoromethyl) pyridinecarboxamide
- Trifluoroacetic acid (4.0mL) was added to a stirred solution of tert-butyl 4-(3-(4-(6-methoxy-5-(6-(trifluoromethyl) pyridinecarboxamido))-2H-indazol-2-yl) piperidin-1-yl) propyl) piperidine-1-formate (1.4g, 2.1 mmol) in dichloromethane (20.0mL).
- the reaction mixture was stirred at 25 °C for 2 hours, then concentrated under reduced pressure to obtain 1.1g of crude target product. The crude product was used directly for the next step.
- tert-butyl 4-(allyloxy) piperidine-1-carboxylate (1g,4.15mmol) in dichloromethane (30 mL) was reacted at -78 °C for 30 minutes and then quenched with dimethyl sulfide (10mL), concentrated under reduced pressure, and the concentrate was purified by column chromatography to obtain 300mg of the target product.
- Step 3 tert-butyl 4-(2-(4-(6-methoxy-5-(6-(trifluoromethyl) pyridinecarboxamido))-2H-indazol-2-yl) piperidin-1-yl) ethoxy) piperidine-1-carboxylate
- the reaction mixture was diluted with ethyl acetate (60mL) and washed with water (2 ⁇ 60mL) and saturated saline (60mL).
- the organic phase was collected and dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure.
- the concentrate was purified on a silica gel column to obtain 260mg of the target product.
- Step 4 N-(6-methoxy-2-(1-(2-(piperidin-4-yloxy) ethyl) piperidin-4-yl)-2H-indazol-5-yl)-6-(trifluoromethyl) pyridinecarboxamide
- Step 1 tert-butyl 9-((4-(6-(2-hydroxyprop -2-yl)-5-(6-(trifluoromethyl) pyridinecarboxamido)-2H-indazol-2-yl) piperidin-1-yl) methyl)-3-azaspiro[5.5] undecyl-3-carboxylate
- Step 2 N-(2-(1-((3-azaspiro[5.5] undec-9-yl) methyl) piperidin-4-yl)-6-(2-hydroxyprop-2-yl)-2H-indazol-5-yl)-6-(trifluoromethyl) pyridinecarboxamide
- Step 1 Preparation of tert-butyl 4-(2-(4-(6-methoxy-5-(6-(trifluoromethyl) pyridinecarboxamido))-2H-indazol-2-yl) piperidin-1-yl) ethyl) piperazine-1-carboxylate
- reaction solution was stirred and reacted overnight at room temperature, the resulting reaction solution was diluted with ethyl acetate (20mL), washed with water (2 ⁇ 20mL) and saturated saline (20mL), and the organic phase was collected. The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The concentrate was purified by column chromatography to obtain 80 mg of target product as a yellow oil.
- Step 2 N-(6-methoxy-2-(1-(2-(piperazin-1-yl) ethyl) piperidin-4-yl)-2H-indazol-5-yl)-6-(trifluoromethyl) pyridinecarboxamide
- Step 1 Preparation of tert-butyl 4-(2-(4-(6-methoxy-5-(6-(trifluoromethyl) pyridinecarboxamido)-2H-indazol-2-yl) piperidin-1-yl) methyl) piperidine-1-formate
- the reaction solution was diluted with ethyl acetate (50mL), washed with water (2 ⁇ 50mL) and saturated saline (50mL), the organic phase was collected, dried over anhydrous sodium sulfate, and concentrated under reduced pressure.
- the concentrate was purified by column chromatography to obtain 550 mg of target product as a yellow solid.
- Step 2 Preparation of N-(6-methoxy-2-(1-(2-(piperidin-4-yl) methyl) piperidin-4-yl)-2H-indazol-5-yl)-6-(trifluoromethyl) pyridinecarboxamide
- Step 1 Preparation of tert-butyl 4-(2-(4-(6-methoxy-5-(6-(trifluoromethyl) pyridinecarboxamido)-2H-indazol-2-yl) piperidin-1-yl) methyl) piperidine-1-formate
- the reaction solution was diluted with ethyl acetate (50mL), washed with water (2 ⁇ 50mL) and saturated saline (50mL), and the organic phase was collected, dried over anhydrous sodium sulfate, and concentrated under reduced pressure.
- the concentrate was purified by column chromatography to obtain 550 mg of target product as a yellow solid.
- Step 2 Preparation of N-(6-methoxy-2-(1-(2-(piperidin-4-yl) methyl) piperidin-4-yl)-2H-indazol-5-yl)-6-(trifluoromethyl) pyridinecarboxamide
- Step 2 ((1R,4R)-4-(5-amino-6-methoxy-2H-indazol-2-yl) cyclohexyl) methanol
- Step 3 N-(2-((1R,4R)-4-(hydroxymethyl) cyclohexyl)-6-methoxy-2H-indazol-5-yl)-6-(trifluoromethyl) pyridinecarboxamide
- Step 4 N-(2-((1R,4R)-4-formylcyclohexyl)-6-methoxy-2H-indazol-5-yl)-6-(trifluoromethyl) pyridinecarboxamide
- 2-Iodoacyl benzoic acid (404mg,1.0mmol) was added to a mixture of N-(2-((1R,4R)-4-(hydroxymethyl) cyclohexyl)-6-methoxy-2H-indazol-5-yl)-6-(trifluoromethyl) pyridinecarboxamide (224 mg,0.5 mmol) in acetonitrile (10mL), the reaction mixture was heated to 80°C and stirred for 2h. The reaction solution was concentrated under reduced pressure, and the concentrate was purified by column chromatography to obtain 180mg of target product as a brown solid.
- Step 2 ethyl (1s, 4s)-4-(toluenesulfonyloxy) cyclohexane-1-carboxylate
- p-Toluenesulfonyl chloride (12g, 62 mmol), TEA (16g, 156 mmol) and 4-dimethylaminopyridine(61mg,0.5 mmol) were added to a mixture of ethyl (1s, 4s)-4-hydroxycyclohexane-1-carboxylate (9.0g, 12 mmol) in dichloromethane (150 mL).
- the reaction mixture was stirred at room temperature for 16 hours.
- the reaction mixture was concentrated under reduced pressure, and the concentrate was purified by column chromatography to obtain 11g of the target compound as a yellow solid.
- Step 3 (1s, 4s)-4-(hydroxymethyl) cyclohexyl 4-methylbenzenesulfonate
- lithium aluminum hydride 24mL was added to a solution of ethyl (1s, 4s)-4-(toluenesulfonyloxy) cyclohexane-1-carboxylate (5.0g,15.3mmol) in tetrahydrofuran (50mL).
- the reaction mixture was stirred at 0°Cfor 2 hours.
- Sodium sulfate decahydrate was added, filtered and the filtrate was concentrated to obtain 3.6g of target compound as a colorless solid .
- Step 4 N-(2-((1r,4r)-4-(hydroxymethyl) cyclohexyl)-6-(2-hydroxyprop-2-yl)-2H-indazol-5-yl)-6-(trifluoromethyl) pyridinecarboxamide
- Step 5 N-(2-((1r,4r)-4-formylcyclohexanyl)-6-(2-hydroxyprop-2-yl)-2H-indazol-5-yl)-6-(trifluoromethyl) pyridinecarboxamide
- Step 1 tert-butyl 4-(2-((((1R,4R)-4-(6-methoxy-5-(6-(trifluoromethyl) pyridinecarboxamido)-2H-indazol-2-yl) cyclohexyl) methyl) amino) ethyl) piperidine-1-formate
- Step 2 tert-butyl 4-(2-((((1R,4R)-4-(6-methoxy-5-(6-(trifluoromethyl) pyridineformyl)-2H-indazol-2-yl) cyclohexyl) methyl) (methyl) amino) ethyl) piperidine-1-carboxylate
- sodium triacetoxyborohydride (276 mg, 1.3 mmol) was added to a mixture of tert-butyl 4-(2-((((1R,4R)-4-(6-methoxy-5-(6-(trifluoromethyl) pyridinecarboxamido)-2H-indazol-2-yl) cyclohexyl) methyl) amino) ethyl) piperidine-1-formate (170 mg,0.26 mmol) and formaldehyde (37wt% aqueous solution, 162 mg,2 mmol) in tetrahydrofuran (10 mL), and the reaction mixture was stirred for reaction overnight.
- Step 3 N-(6-methoxy-2-((1R,4R)-4-((methyl (2-(piperidin-4-yl) ethyl) amino) methyl) cyclohexyl)-2H-indazol-5-yl)-6-(trifluoromethyl) pyridinecarboxamide
- the reaction mixture was quenched with water (50mL) and extracted with dichloromethane (3 ⁇ 20mL), the organic layer was collected, washed with saturated saline (60mL), dried over anhydrous sodium sulfate, filtered and concentrated.
- the concentrate was purified by column chromatography to obtain 120mg of target product as a light yellow solid.
- Step 2 N-(6-methoxy-2-((1r,4r)-4-((methyl (piperidin-4-ylmethyl) amino) methyl) cyclohexyl)-2H-indazol-5-yl)-6-(trifluoromethyl) pyridinecarboxamide
- Trifluoroacetic acid (2mL) was added to a mixture of tert-butyl 4-((((1r,4r)-4-(6-methoxy-5-(6-(trifluoromethyl) pyridinecarboxamido)-2H-indazol-2-yl) cyclohexyl) methyl) (methyl) amino) methyl) piperidine-1-formate (120mg,0.18mmol) in dichloromethane (5mL). The reaction mixture was stirred at room temperature for 2h. The reaction mixture was concentrated, to obtain 200 mg of crude target product as a light yellow solid was obtained. The crude product was used directly for the next step.
- Step 2 tert-butyl 9-amino-3-azaspiro[5.5] undecyl-3-carboxylate
- Step 1 tert-butyl ((1r,4r)-4-(6-methoxy-5-nitro-2H-indazol-2-yl) cyclohexyl) carbamate
- Step 2 tert-butyl ((1r,4r)-4-(5-amino-6-methoxy-2H-indazol-2-yl) cyclohexyl) carbamate
- Step 3 tert-butyl ((1r, 4r)-4-(6-methoxy-5-(6-(trifluoromethyl) pyridinecarboxamido)-2H-indazol-2-yl) cyclohexyl) carbamate
- 6-(Trifluoromethyl) picolinic acid (609mg,3.19 mmol), HATU(1.5g, 4.0mmol) and N,N-diisopropylethylamine(1.2g,9.3mmol) were added to a mixture of tert-butyl ((1r,4r)-4-(5-amino-6-methoxy-2H-indazol-2-yl) cyclohexyl) carbamate (1.15g, 3.19 mmol) in N,N-dimethylformamide (10mL). The reaction mixture was stirred at room temperature for 2 hours, and the reaction was quenched with water (100mL), and extracted with ethyl acetate (3 ⁇ 50mL). The organic layers were collected and washed with saturated saline (150mL), dried over anhydrous sodium sulfate, filtered and concentrated. The concentrate was purified by column chromatography to obtain 1.3g of crude target product as a yellow solid.
- Step 4 N-(2-((1r,4r)-4-aminocyclohexyl)-6-methoxy-2H-indazol-5-yl)-6-(trifluoromethyl) pyridinecarboxamide
- Step 5 tert-butyl 9-(((1r,4r)-4-(6-methoxy-5-(6-(trifluoromethyl) pyridinecarboxamido)-2H-indazol-2-yl) cyclohexyl) amino)-3-azaspiro[5.5] undecyl-3-carboxylate
- Step 6 tert-butyl 9-(((1r,4r)-4-(6-methoxy-5-(6-(trifluoromethyl) pyridinecarboxamido)-2H-indazol-2-yl) cyclohexyl) (methyl) amino)-3-azaspiro[5.5] undecyl-3-carboxylate
- Step 7 N-(6-methoxy-2-((1r,4r)-4-(methyl (3-azaspiro[5.5] undec-9-yl) amino) cyclohexyl)-2H-indazol-5-yl)-6-(trifluoromethyl) pyridinecarboxamide
- Step 3 tert-butyl 9-(6-methoxy-5-(6-(trifluoromethyl) pyridinecarboxamido)-2H-indazol-2-yl)-3-azaspiro[5.5] undecyl-3-carboxylate
- 6-(Trifluoromethyl) picolinic acid (208mg, 1.09 mmol), HATU(538mg, 1.42mmol) and N,N-diisopropylethylamine(554mg,4.26mmol) were added to a mixture of tert-butyl 9-(5-amino-6-methoxy-2H-indazol-2-yl)-3-azaspiro[5.5] undecyl -3-carboxylate (450 mg, 1.09 mmol) in N,N-dimethylformamide (10 mL), and the reaction mixture was stirred at room temperature for 2 hours.
- the reaction was quenched with water (100mL) and extracted with ethyl acetate (3 ⁇ 50mL). The organic layer was collected and washed with saturated saline (150mL), dried over anhydrous sodium sulfate, filtered and concentrated. The concentrate was purified by chromatography to obtain 600mg of the target product as a light yellow solid.
- Step 4 N-(6-methoxy-2-(3-azaspiro[5.5] undec-9-yl)-2H-indazol-5-yl)-6-(trifluoromethyl) pyridinecarboxamide
- Trifluoroacetic acid (2 mL) was added to a mixture of tert-butyl 9-(6-methoxy-5-(6-(trifluoromethyl) pyridinecarboxamido)-2H-indazol-2-yl)-3-azaspiro[5.5] undecyl-3-carboxylate (200mg,0.34 mmol) in dichloromethane (5 mL).
- the reaction mixture was stirred at room temperature for 2 hours, and concentrated under reduced pressure to obtain 270mg of the desired crude target product as a light yellow solid, which was directly used for the next step.
- Step 5 tert-butyl 4-((9-(6-methoxy-5-(6-(trifluoromethyl) pyridinecarboxamido)-2H-indazol-2-yl)-3-azaspiro[5.5] undec-3-yl) methyl) piperidine-1-carboxylate
- the reaction was quenched with water (50mL) and extracted with dichloromethane (3 ⁇ 20mL), and the organic layer was collected, washed with saturated saline (60mL), dried over anhydrous sodium sulfate, filtered and concentrated.
- the concentrate was purified by column chromatography to obtain 130mg of target product as a light yellow solid.
- Step 6 N-(6-methoxy-2-(3-(piperidin-4-ylmethyl)-3-azaspiro [5.5] undec-9-yl)-2H-indazol-5-yl)-6-(trifluoromethyl) pyridinecarboxamide
- Trifluoroacetic acid (2mL) was added to a stirred mixture of tert-butyl 4-((9-(6-methoxy-5-(6-(trifluoromethyl) pyridinecarboxamido)-2H-indazol-2-yl)-3-azaspiro [5.5] undec-3-yl) methyl) piperidine-1-carboxylate (130mg,0.19mmol) in dichloromethane (5mL).
- the reaction mixture was stirred at room temperature for 2 hours.
- the reaction mixture was concentrated to obtain 220mg of crude target product as a light yellow solid, and the crude product was directly used for the next step.
- Trifluoroacetic acid (5mL) was added to a solution of tert-butyl (4-oxocyclohexyl) carbamate (2.13g,10mmol) in dichloromethane (20mL), and the reaction mixture was stirred at room temperature for 3 hours. The reaction mixture was concentrated under reduced pressure to obtain 2.1g of the crude target product, which can be used for the next step without further purification.
- 2-Azido-4-methoxy-5-nitrobenzaldehyde (2.22g, 10 mmol) was added to a reaction mixture of 4-aminocyclohexyl-1-one (crude, 2.1g) in toluene (50mL), and the reaction mixture was heated to 100°C and stirred for reaction overnight, and concentrated under reduced pressure. The concentrate was purified by column chromatography to obtain 1.5g of target compound as a yellow solid.
- the organic layer was collected, washed with saturated saline (200mL), dried over anhydrous sodium sulfate, filtered and concentrated.
- the concentrate was purified by column chromatography to obtain the target products P1:150mg and P2:160 mg as a light yellow solid.
- Step 1 tert-butyl 9-((1s, 4s)-4-(5-amino-6-methoxy-2H-indazol-2-yl) cyclohexyl)-3, 9-diazaspiro [5.5] undecyl-3-carboxylate
- Step 2 tert-butyl 9-((1s, 4s)-4-(6-methoxy-5-(6-(trifluoromethyl) pyridinecarboxamido)-2H-indazol-2-yl) cyclohexyl)-3, 9-diazaspiro[5.5] undecyl-3-carboxylate
- 6-(Trifluoromethyl) picolinic acid (58mg,0.30mmol), HATU(149mg,0.39mmol) and N,N-diisopropylethylamine(117mg,0.90mmol) were added to a stirred solution of tert-butyl 9-((1s, 4s)-4-(5-amino-6-methoxy-2H-indazol-2-yl) cyclohexyl)-3, 9-diazaspiro [5.5] undecyl-3-carboxylate (140mg,0.23mmol) in N,N-dimethylformamide (3mL). The resulting reaction mixture was stirred for 2 hours at room temperature.
- the reaction mixture was quenched with water (50mL), and extracted with ethyl acetate (3 ⁇ 20mL). The organic layers were collected and washed with saturated saline (60mL), dried over anhydrous sodium sulfate, filtered and concentrated. The concentrate was purified by chromatographic column to obtain 90mg of target product as light yellow solid.
- Step 3 N-(2-((1s, 4s)-4-(3, 9-diazaspiro [5.5] undec-3-yl) cyclohexyl)-6-methoxy-2H-indazol-5-yl)-6-(trifluoromethyl) pyridinecarboxamide
- Trifluoroacetic acid (2mL) was added to a solution of tert-butyl 9-((1s, 4s)-4-(6-methoxy-5-(6-(trifluoromethyl) pyridinecarboxamido)-2H-indazol-2-yl) cyclohexyl)-3, 9-diazaspiro[5.5] undecyl-3-carboxylate (90mg,0.13mmol) in dichloromethane (5mL). The resulting reaction mixture was stirred for 2 hours at room temperature. The reaction mixture was concentrated to obtain 120mg of the crude target product as a light yellow solid.
- Benzyl carbonyl chloride (5.06g, 29.8 mmol) was added to a mixture of 2-(piperidin-4-yl) ethyl-1-ol (3.2g, 24.8 mmol) in saturated sodium bicarbonate aqueous solution (30 mL) and water (30 mL). The reaction mixture was stirred overnight at room temperature, and extracted with ethyl acetate (3 ⁇ 100mL). The organic layer was collected, washed with saturated saline (50mL), dried over anhydrous sodium sulfate, filtered and concentrated. The concentrate was purified by column chromatography to obtain 6.0g of the target product as a yellow oil.
- Step 2 benzyl 4-(2-(toluenesulfonyloxy) ethyl) piperidine-1-carboxylate
- Step 3 benzyl 4-(2-(((1r, 4r)-4-((tert-butoxycarbonyl) amino) cyclohexyl) methoxy) ethyl) piperidine-1-carboxylate
- Step 4 benzyl 4-(2-(((1r, 4r)-4-aminocyclohexyl) methoxy) ethyl) piperidine-1-carboxylate
- Trifluoroacetic acid (20 mL) was added to a solution of benzyl 4-(2-(((1r, 4r)-4-((tert-butoxycarbonyl) amino) cyclohexyl) methoxy) ethyl) piperidine-1-carboxylate (1.4g,2.95mmol) in dichloromethane (50 mL), and the reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated under reduced pressure to obtain 1.4g of crude target product. It can be used for the next step without further purification.
- Step 5 benzyl 4-(2-(((1r, 4r)-4-(6-methoxy-5-nitro-2H-indazol-2-yl) cyclohexyl) methoxy) ethyl) piperidine-1-carboxylate
- Step 6 benzyl 4-(2-(((1r, 4r)-4-(5-amino-6-methoxy-2H-indazol-2-yl) cyclohexyl) methoxy) ethyl) piperidine-1-carboxylate
- Step 7 benzyl 4-(2-(((1r,4r)-4-(6-methoxy-5-(6-(trifluoromethyl) pyridinecarboxamido)-2H-indazol-2-yl) cyclohexyl) methoxy) ethyl) piperidine-1-carboxylate
- 6-(Trifluoromethyl) picolinic acid (184mg, 0.96mmol), HATU(474mg,1.25mmol) and N,N-diisopropylethylamine(372mg,2.88mmol) were added to a mixture of benzyl 4-(2-(((1r, 4r)-4-(5-amino-6-methoxy-2H-indazol-2-yl) cyclohexyl) methoxy) ethyl) piperidine-1-carboxylate(500mg,0.96mmol) in N,N-dimethylformamide (10mL). The reaction mixture was stirred at room temperature for 2 hours. The reaction was quenched with water (20mL).
- Step 8 N-(6-methoxy-2-((1r,4r)-4-((2-(piperidin-4-yl) ethoxy) methyl) cyclohexyl)-2H-indazol-5-yl)-6-(trifluoromethyl) pyridinecarboxamide
- N-(6-methoxy-2-((1r,4r)-4-((methyl (piperidin-4-yl) amino) methyl) cyclohexyl)-2H-indazol-5-yl)-6-(trifluoromethyl) pyridinecarboxamide (280 mg, 0.40 mmol) and tert-butyl 4-oxopiperidine-1-carboxylate (88 mg, 0.44 mmol) were dissolved with 1,2-dichloroethane (20 mL), the temperature was increased to 70 °C, three drops of acetic acid were added, sodium triacetoxyborohydride (844 mg, 4.0 mmol) was divided into five parts, one part was added to the reaction solution every 1 hour, and stirred overnight at 70 °C.
- reaction solution was cooled to room temperature, added with water (30 mL), extracted with dichloromethane (3x20 mL), and the organic phase was washed with saturated saline (50 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the crude product was purified by column chromatography to obtain 70 mg of target product as a light yellow solid.
- step 2 N-(2-((1r,4r)-4-(([1,4'-bipiperidin]-4-yl (methyl) amino) methyl) cyclohexyl)-6-methoxy-2H-indazol-5-yl)-6-(trifluoromethyl) pyridinecarboxamide
- Step 4 tert-butyl 4-(6-(difluoromethoxy)-5-(6-(trifluoromethyl) pyridinecarboxamido)-2H-indazol-2-yl) piperidine-1-carboxylate
- Step 6 tert-butyl 9-((4-(6-(difluoromethoxy)-5-(6-(trifluoromethyl) pyridinecarboxamido)-2H-indazol-2-yl) piperidin-1-yl) methyl)-3-azaspiro[5.5] undecyl-3-carboxylate
- N-(6-(difluoromethoxy)-2-(piperidin-4-yl)-2H-indazol-5-yl)-6-(trifluoromethyl) pyridinecarboxamide (220 mg) and tert-butyl 9-formyl-3-azaspiro[5.5] undecyl-3-carboxylate (109 mg, 0.38 mmol) were dissolved in tetrahydrofuran (10 mL), stirred at room temperature, sodium triacetoxyborohydride (371 mg, 1.76 mmol) was added and stirred at room temperature for 2 hours, water (30 mL) was added, extracted with dichloromethane (3 ⁇ 30 mL), the organic phase was washed with saturated saline (100 mL), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the crude product was purified by column chromatography to obtain 100 mg of the target product.
- Step 7 N-(2-(1-((3-azaspiro[5.5] undec-9-yl) methyl) piperidin-4-yl)-6-(difluoromethoxy)-2H-indazol-5-yl)-6-(trifluoromethyl)) pyridinecarboxamide
- Step 4 tert-butyl 9-((4-(5-amino-6-(2-methoxyethoxy)-2H-indazol-2-yl) piperidin-1-yl) methyl)-3-azaspiro[5.5] undecyl-3-carboxylate
- Step 5 tert-butyl 9-((4-(6-(2-methoxyethoxy))-5-(6-(trifluoromethyl) pyridinecarboxamido)-2H-indazol-2-yl) piperidin-1-yl) methyl)-3-azaspiro[5.5] undecyl-3-carboxylate
- Step 6 N-(2-(1-((3-azaspiro[5.5] undec-9-yl) methyl) piperidin-4-yl)-6-(2-methoxyethoxy)-2H-indazol-5-yl)-6-(trifluoromethyl) pyridinecarboxamide
- Step 1 tert-butyl 1(1r,4r)-4-((pyridin-4-ylmethoxy) methyl) cyclohexyl) carbamate
- Step 2 tert-butyl ((1r,4r)-4-((piperidin-4-ylmethoxy) methyl) cyclohexyl) carbamate
- Step 3 benzyl 4-((((1r,4r)-4-((tert-butoxycarbonyl) amino) cyclohexyl) methoxy) methyl) piperidine-1-carboxylate
- Example 1 N-(2-(1-(2-(9-(3-(2, 4-dioxotetrahydropyrimidin-1 (2H)-yl)-4-methoxybenzoyl)-3, 9-diazaspiro[5.5] undec-3-yl) ethyl) piperidin-4-yl)-6-methoxy-2H-indazol-5-yl)-6-(trifluoromethyl)-2-pyridinecarboxamide
- N-(6-methoxy-2-(piperidin-4-yl)-2H-indazol-5-yl)-6-(trifluoromethyl) pyridinecarboxamide (95 mg, 0.226 mmol) was added to a mixture of 2-(9-(3-(2, 4-dioxo tetrahydropyrimidin-1 (2H)-yl)-4-methoxybenzoyl)-3,9-diazaspiro[5.5] undec-3-yl) acetaldehyde (100 mg, 0.226 mmol) and sodium cyanoborohydride (28mg,0.452mmol) in methanol/acetic acid (4mL,10:1). The mixture was stirred at room temperature for 4h, concentrated under reduced pressure, and the concentrate was purified by preparative HPLC to obtain 11.23 mg of the target compound as a light yellow solid.
- Example Structure Name LC-MS/NMR
- Example 2 N-(2-(1-(3-(9-(3-(2,4-dioxotetrahydropyrimidi n-1 (2H)-yl)-4-methoxybenzoyl)-3, 9-diazaspiro [5.5] undec-3-yl) propyl) piperidin-4-yl)-6-methoxy-2H-indazol-5-yl)-6-(trifluoromethyl)-2-pyridinecarboxamide
- LC-MS:(ESI, m / z ):[M+H] + 860.4.
- the reaction solution was poured into water (20mL) and extracted with ethyl acetate (3 ⁇ 20mL), the organic phase was collected, washed with water (2 ⁇ 50mL) and saline (50mL), dried over anhydrous sodium sulfate, filtered and concentrated.
- the concentrate was purified by preparative HPLC to obtain 19.97mg of target product as a light yellow solid.
- Example 7 N-(2-(1-(2-(1-(3-(2, 4-dioxotetrahydropyrimidin-1 (2H)-yl)-4-methoxybenzoyl) piperidin-4-yl) ethyl) piperidin-4-yl) -6-(2-hydroxyprop-2-yl)-2H-indazol-5-yl)-6-(trifluoromethyl) pyridinecarboxamide
- Example 10 N-(2-(1-(2-(9-(3-(2, 4-dioxotetrahydropyrimidin-1 (2H)-yl)-4-methoxybenzoyl)-3, 9-diazaspiro[5.5] undec-3-yl) ethyl) piperidin-4-yl)-6-(2-hydroxyprop-2-yl)-2H-indazol-5-yl)-6-(trifluoromethyl) pyridinecarboxamide
- Example 14 N-(2-(1-(2-(4-(3-(2, 4-dioxotetrahydropyrimidin-1 (2H)-yl)-4-methoxybenzoyl) piperazin-1-yl) ethyl) piperidin-4-yl)-6-methoxy-2H-indazol-5-yl) -6-(trifluoromethyl) pyridinecarboxamide
- the reaction solution was poured into water (50mL) and stirred for 0.5h, the solution was extracted with ethyl acetate (3 ⁇ 50mL), and the organic phase was collected, washed with water (2 ⁇ 100mL) and saturated saline (100mL), dried over anhydrous sodium sulfate, filtered and concentrated.
- the concentrate was purified by preparative HPLC to obtain 28.57mg of target product as a yellow solid.
- Example 71 methyl (3-(2-chloro-5-(9-(2-(4-(6-(2-hydroxyprop-2-yl)-5-(6-(trifluoromethyl) pyridinecarboxamido)-2H-indazol-2-yl) piperidin-1-yl) ethyl)-3-azaspiro[5.5] undecyl-3-carbonyl) phenyl)-2, 6-dioxotetrahydropyrimidin-1 (2H)-yl) pivalate
- Control group 1 N-(2-(1-(2-(2-((2-(2, 6-dioxopiperidin-3-yl)-1, 3-dioxoisoindol-5-yl) oxy) ethoxy) ethyl) piperidin-4-yl)-6-methoxy-2H-indazol-5-yl)-6-(trifluoromethyl) pyridinecarboxamide
- Step 1 Preparation of 2-(2, 6-dioxopiperidin-3-yl)-5-(2-(2-hydroxyethoxy) ethoxy) isoindolin-1, 3-dione
- N,N-diisopropylethylamine(706.2mg,0.0055mol) and potassium iodide (30mg,0.0002mol) were added dropwise to a mixture of 2-(2,6-dioxopiperidin-3-yl)-5-hydroxyisoindolin-1,3-dione (500 mg, 0.0018 mol) and 2-(2-chloroethoxy)ethyl-1-ol (227 mg, 0.0018 mol) in dimethylsulfoxide (20 mL).
- the reaction solution was stirred at 100 °C for 10h.
- Step 2 Preparation of 2-(2-((2-(2, 6-dioxopiperidin-3-yl)-1, 3-dioxoisoindolin-5-yl) oxy) ethoxy) acetaldehyde
- Dess-martin(393mg,0.88mmol) was added to a mixture of 2-(2, 6-dioxopiperidin-3-yl)-5-(2-(2-hydroxyethoxy) ethoxy) isoindolin-1, 3-dione (162 mg,0.44 mmol) in tetrahydrofuran (10 mL) at 0 °C, and the obtained reaction solution was stirred for 16 hours at room temperature. The reaction solution was quenched with water (30ml) and dichloromethane (50ml). The water layer was separated and extracted with dichloromethane (50ml ⁇ 2).
- Step 3 preparation of N-(2-(1-(2-(2-((2-(2, 6-dioxopiperidin-3-yl)-1, 3-dioxoisoindol-5-yl) oxy) ethoxy) ethyl) piperidin-4-yl)-6-methoxy-2H-indazol-5-yl)-6-(trifluoromethyl) pyridinecarboxamide
- Control group 2 N-(2-(1-((1-(2-((2-(2, 6-dioxopiperidin-3-yl)-1, 3-dioxoisoindol-5-yl) oxy) ethyl) piperidin-4-yl) methyl) piperidin-4-yl)-6-methoxy-2H-indazol-5-yl)-6-(trifluoromethyl) pyridinecarboxamide
- Step 2 2-((2-(2,6-dioxopiperidin-3-yl)-1, 3-dioxoisoindolin-5-yl) oxy) acetaldehyde
- Ozone was introduced into a solution of 5-(allyloxy)-2-(2, 6-dioxopiperidin-3-yl) isoindolin-1, 3-dione (0.7g,2.23mmol) in methylene chloride (200ml) at -78°C until the reaction solution turned to be blue. Then nitrogen was introduced until the reaction solution became colorless. Dimethyl sulfide (7.61g,123mmol) was added at -78 °C under nitrogen protection, and the reaction mixture was stirred at room temperature overnight. The reaction solution was concentrated, and the concentrate was purified by column chromatography to obtain the target product.
- Step 3 Preparation of N-(2-(1-((1-(2-((2-(2, 6-dioxopiperidin-3-yl)-1, 3-dioxoisoindol-5-yl) oxy) ethyl) piperidin-4-yl) methyl) piperidin-4-yl)-6-methoxy-2H-indazol-5-yl)-6-(trifluoromethyl) pyridinecarboxamide
- Control group 3 N-(2-((1r,4r)-4-((((1-(2-(2, 6-dioxopiperidin-3-yl)-1, 3-dioxoisoindolin-4-yl) piperidin-4-yl) methyl) (methyl) amino) methyl) cyclohexyl)-6-(2-hydroxyprop-2-yl)-2H-indazol-5-yl)-6-(trifluoromethyl) pyridinecarboxamide
- Test Example 1 IRAK4 kinase activity test
- KinEASE-STK S1 serine/threonine kinase kit (Cisbio) was used to detect the inhibitory effect of the compound on IRAK4 kinase activity.
- the specific method was: the compound was dissolved in dimethyl sulfoxide, and then it was diluted with the buffer solution of the kit by equal gradient to make the final concentration range of the tested compound in the reaction system 10000 nM-0.038 nM, then 2.5 nM kinase, 1 ⁇ M biotinylated polypeptide substrate and 7 ⁇ M adenosine triphosphate (ATP) were added in sequence and incubated at 37 °C for 120 min.
- ATP adenosine triphosphate
- the compound of the invention can effectively bind with the target protein and inhibit the IRAK4 kinase activity.
- Test Example 2 Degradation of IRAK4 in THP-1 Cells by Compounds
- Each well of the 24-well cell culture plate was inoculated with 0.95 mL THP-1 cells (stem cell bank of Chinese academy of sciences) with a cell density of 5 ⁇ 10 5 cells/well.
- the cell plate was placed in a 5% carbon dioxide incubator and cultured overnight at 37 °C, then 50 ⁇ L compound in dimethyl sulfoxide was added. The final concentration of the compound was in the range of 1-3000 nM. After continuous cultivation for 24 hours, the cells were collected into a 1.5 mL centrifuge tube, centrifuged at 1000 rpm and 4 °C for 5 minutes.
- Cell precipitation was cleaned twice with 1 ⁇ DPBS, resuspended cells were lysed with 200 ⁇ L lysate (cell lysate was Western and IP cell lysate (Beyotime), supplemented with 1 mM mixture of phenylmethylsulfonyl fluoride and protease inhibitor (Beyotime)), left on ice for 30 minutes, then centrifuged at 14000g at 4 °C for 10 minutes, and the supernatant was taken to detect IRAK4 protein level by Western blot.
- PVDF membranes were incubated with IRAK4 primary antibody (Abcam) overnight at 4°, the membranes were washed with TBST buffer (2.4g Tris,8.8g NaCl,1.5 mL Tween 20, pH adjusted to 7.4, constant volume to 1L) for 30 minutes, incubated with secondary antibody (Abcam) for 2 hours at room temperature, finally incubated with Clarity Western ECL Substrate(BIO-RAD) for 5 minutes for luminescence development, chemiluminescence imaging system (Clinx, chemiScope 6200 Touch) for development and protein mapping photography. The protein map was analyzed by Clinx chemiluminescence analysis software for grayscale values.
- grayscale correction value (target protein grayscale value/corresponding internal reference grayscale value) ⁇ 10 3 .
- the degradation rate was calculated by comparing with the grayscale correction value of the control group.
- DC 50 and D max values of the compound were obtained by the nonlinear curve fitting with the logarithmic concentration-inhibition rate by GraphPad Prism 7.
- the compound of the present invention can effectively degrade IRAK4 kinase protein in THP-1 cells and has excellent degradation activity.
- Test Example 3 Degradation of IKZF1 and IKZF3 in L363 Cells by Compound
- the 24-well cell culture plate was inoculated with 0.95 mL L363 cells (Nanjing Co-bioer) per well with a cell density of 6 ⁇ 10 5 cells/well.
- the cell plate was placed in a 5% carbon dioxide incubator and cultured at 37 °C for 8 hours, then 50 ⁇ L of compound solution was added. The final concentration of the compound was 1000 nM. After continuing to culture for 16 hours, the cells were collected into a 1.5 mL centrifuge tube and centrifuged at 3000 rpm and 4 °C for 5 minutes.
- Cell precipitation was cleaned twice with 1 ⁇ DPBS, resuspended cells were lysed with 100 ⁇ L lysate (cell lysate was Western and IP cell lysate (Beyotime), supplemented with 1 mM mixture of phenylmethylsulfonyl fluoride and protease inhibitor (Beyotime)), left on ice for 30 minutes, then centrifuged at 14000g at 4 °C for 10 minutes, and the supernatant was taken to detect IKZF1 and IKZF3 protein level by Western blot.
- the total protein concentration in the supernatant of cell lysis was determined by BCA protein quantitative kit (Tiangen). According to the concentration of total protein detected by BCA, the supernatant was adjusted to 0.2 ⁇ g/ ⁇ L with PBS and 5 ⁇ SDS-PAGE protein loading buffer (Beyotime), bathed in water at 100 °C for 10 minutes, then placed in ice bath for 5 minutes, centrifuged at 14000g and 4 °C for 5 minutes, and then collected as WB loading sample. Prefabricated glue (KeyGEN) was used for protein electrophoresis with a loading amount of 10 ⁇ L (total protein 2 ⁇ g).
- PVDF membranes were incubated with IKZF1 primary antibody (CST) and IKZF3 primary antibody (Abcam) overnight at 4°, the membranes were washed with TBST buffer (2.4g Tris,8.8g NaCl,1.5 mL Tween 20, pH adjusted to 7.4, constant volume to 1L) for 30 minutes, incubated with secondary antibody (Abcam) for 2 hours at room temperature, finally incubated with Clarity Western ECL Substrate(BIO-RAD) for 5 minutes for luminescence development, chemiluminescence imaging system (Clinx, chemiScope 6200 Touch) for development and protein mapping photography. The protein map was analyzed by Clinx chemiluminescence analysis software for grayscale values.
- grayscale correction value (target protein grayscale value/corresponding internal reference grayscale value) ⁇ 10 3
- the degradation rate was calculated by comparing with the grayscale correction value of the control group.
- Table 3 Compound Concentration (nM) IKZF1 degradation rate (%) IKZF3 degradation rate (%) Pomalidomide 1000 99.7 ⁇ 0.2 98.6 ⁇ 0.6
- Control group 2 1000 47.5 ⁇ 9.7 71.2 ⁇ 5.7
- Control group 3 1000 97.2 ⁇ 2.6 92.8 ⁇ 5.0
- Example 34 1000 10.2 ⁇ 1.8 -2.2 ⁇ 2.8
- Example 31 1000 8.4 ⁇ 13.9 17.8 ⁇ 3.6
- "-" refers to no degradation of IKZF1 and IKZF3.
- the experimental results show that the compound of the present invention has good degradation selectivity, no or a small amount of degradation to IKZF1 and IKZF3, and has small toxic side effects, which is beneficial to the patent medicine.
- Frozen human PBMC (Milestone, PB010C) was resuspended to RPMI 1640 medium (Gibco,A1049101) after resuscitation, supplemented with 10% fetal bovine serum (Gibco,10099141),100 U/mL penicillin and 100 ⁇ g/mL streptomycin (Gibco,15140122).
- 150 ⁇ L of PBMC was spread in each well of a 96-well transparent cell plate (Labserv,310109008), so that the cell density was 2 ⁇ 105 cells/well.
- the cell plate was again placed in a 5% CO2 incubator at 37 °C for 5 hours, centrifuged at 2000 rpm for 10 minutes, and 100 ⁇ L cell supernatant was taken from each well and transferred to a new 96-well transparent cell plate for cytokine concentration test, which was frozen at -80 °C to be tested.
- the concentration of IL-6 in the supernatant of LPS-induced human PBMC cells was determined using interleukin-6 (IL-6)AlphaLISA detection kit (PerkinElmer,AL223 C).
- IL-6 standard solutions with different concentrations were prepared in the concentration range of 0-100000 pg/mL.
- 2 ⁇ L of IL-6 standard solution at various concentrations and the cell supernatant sample to be tested were taken, respectively added to white 384 well plates (PerkinElmer,6007299), then a mixed solution of 8 ⁇ L of 5 ⁇ anti-IL-6 receptor beads (final concentration: 10 ⁇ g/mL) and biotin-labeled anti-IL-6 antibody (final concentration 1 nM) was added to each well, and incubated at 23 °C for 60 minutes.
- the compounds of the present invention have a good inhibitory effect on IL-6 production by immune cells.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010785541 | 2020-08-05 | ||
CN202011513669 | 2020-12-18 | ||
PCT/CN2021/110990 WO2022028547A1 (zh) | 2020-08-05 | 2021-08-05 | 靶向蛋白降解化合物及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
EP4194457A1 true EP4194457A1 (en) | 2023-06-14 |
Family
ID=80117051
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21852332.2A Pending EP4194457A1 (en) | 2020-08-05 | 2021-08-05 | Compound for targeting and degrading protein, and preparation method therefor and use thereof |
Country Status (12)
Country | Link |
---|---|
US (1) | US20230234936A1 (zh) |
EP (1) | EP4194457A1 (zh) |
JP (1) | JP2023530848A (zh) |
KR (1) | KR20230050375A (zh) |
CN (2) | CN117964623A (zh) |
AU (1) | AU2021323304A1 (zh) |
BR (1) | BR112023002112A2 (zh) |
CA (1) | CA3188258A1 (zh) |
MX (1) | MX2023001566A (zh) |
TW (1) | TWI833104B (zh) |
WO (1) | WO2022028547A1 (zh) |
ZA (1) | ZA202301449B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20240052795A (ko) * | 2021-08-23 | 2024-04-23 | 상하이 리딩택 파마슈티컬 코., 엘티디. | Irak4 분해제 및 이의 제조방법과 응용 |
WO2024094190A1 (zh) * | 2022-11-04 | 2024-05-10 | 上海领泰生物医药科技有限公司 | Irak4降解剂及其用途 |
CN117024413B (zh) * | 2023-10-07 | 2024-01-09 | 天津匠新致成科技有限公司 | 3-氨基吡嗪-2-甲酰胺类靶向蛋白水解嵌合体及其制备方法、药物组合物和应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201614134D0 (en) * | 2016-08-18 | 2016-10-05 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
AU2018215212B2 (en) * | 2017-01-31 | 2022-06-02 | Arvinas Operations, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
US11065231B2 (en) | 2017-11-17 | 2021-07-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides |
EP3727428A1 (en) | 2017-12-20 | 2020-10-28 | Translate Bio, Inc. | Improved composition and methods for treatment of ornithine transcarbamylase deficiency |
EP3752504A4 (en) | 2018-02-14 | 2021-06-09 | Dana Farber Cancer Institute, Inc. | COMPOUNDS DEGRADING THE IRAQ AND USES OF THESE LATEST |
KR20210111252A (ko) | 2018-11-30 | 2021-09-10 | 카이메라 쎄라퓨틱스 인코포레이티드 | Irak 분해제 및 이의 용도 |
-
2021
- 2021-08-05 US US17/999,798 patent/US20230234936A1/en active Pending
- 2021-08-05 WO PCT/CN2021/110990 patent/WO2022028547A1/zh active Application Filing
- 2021-08-05 MX MX2023001566A patent/MX2023001566A/es unknown
- 2021-08-05 AU AU2021323304A patent/AU2021323304A1/en active Pending
- 2021-08-05 BR BR112023002112A patent/BR112023002112A2/pt unknown
- 2021-08-05 CN CN202410106573.6A patent/CN117964623A/zh active Pending
- 2021-08-05 EP EP21852332.2A patent/EP4194457A1/en active Pending
- 2021-08-05 JP JP2022573195A patent/JP2023530848A/ja active Pending
- 2021-08-05 KR KR1020237007867A patent/KR20230050375A/ko active Search and Examination
- 2021-08-05 TW TW110128949A patent/TWI833104B/zh active
- 2021-08-05 CA CA3188258A patent/CA3188258A1/en active Pending
- 2021-08-05 CN CN202180018078.4A patent/CN115244053B/zh active Active
-
2023
- 2023-02-03 ZA ZA2023/01449A patent/ZA202301449B/en unknown
Also Published As
Publication number | Publication date |
---|---|
ZA202301449B (en) | 2024-06-26 |
AU2021323304A1 (en) | 2023-03-02 |
CN115244053B (zh) | 2024-01-30 |
CN117964623A (zh) | 2024-05-03 |
MX2023001566A (es) | 2023-04-13 |
CA3188258A1 (en) | 2022-02-10 |
BR112023002112A2 (pt) | 2023-04-18 |
KR20230050375A (ko) | 2023-04-14 |
JP2023530848A (ja) | 2023-07-20 |
CN115244053A (zh) | 2022-10-25 |
TW202210470A (zh) | 2022-03-16 |
US20230234936A1 (en) | 2023-07-27 |
TWI833104B (zh) | 2024-02-21 |
WO2022028547A1 (zh) | 2022-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW202039498A (zh) | 嘧啶並五員氮雜環類衍生物、其製備方法及其在醫藥上的應用 | |
EP4194457A1 (en) | Compound for targeting and degrading protein, and preparation method therefor and use thereof | |
CN112778276A (zh) | 作为shp2抑制剂的化合物及其应用 | |
TWI823959B (zh) | 吡啶并嘧啶類衍生物、其製備方法及其在醫藥上的應用 | |
TW201900640A (zh) | 作為irak4抑制劑之噻吩并吡啶及苯并噻吩 | |
WO2021115457A1 (zh) | 吡唑并[1,5-a]吡啶类化合物及其制备方法和应用 | |
EP4238968A1 (en) | Indazole derivative, and preparation method therefor and use thereof | |
KR20210136995A (ko) | 브루톤 티로신 키나아제 억제제 | |
EP4342891A1 (en) | Spiro compound and use thereof | |
TW202200575A (zh) | 一種免疫抑制劑、其製備方法和應用 | |
KR20230051528A (ko) | 화합물, 조성물 및 방법 | |
CN112778336B (zh) | 一类含氮稠环类sting调节剂类化合物、制备方法和用途 | |
WO2023109751A1 (zh) | 嘧啶或吡啶类衍生物及其医药用途 | |
JPWO2019189555A1 (ja) | 複素環化合物 | |
WO2023025159A1 (zh) | Irak4降解剂及其制备方法和应用 | |
WO2022253309A1 (zh) | 取代的杂环化合物及其应用 | |
WO2022174765A1 (zh) | 作为Wee-1抑制剂的稠环化合物 | |
WO2022063050A1 (zh) | 吡唑类化合物及其制备方法和用途 | |
WO2019141096A1 (zh) | 取代脲类化合物及其制备方法和用途 | |
CN111763217B (zh) | 一类噻吩并氮杂环类化合物、制备方法和用途 | |
WO2023051464A1 (en) | Pyrazolopyridine compounds as tam inhibitors | |
WO2024002024A1 (zh) | 三环类化合物及其用途 | |
WO2023109883A1 (zh) | 一类芳杂环取代的化合物及其制备方法和用途 | |
CN117143107A (zh) | 1,2-二氢吡啶类衍生物及其制备方法和用途 | |
WO2021238818A1 (zh) | 一种大环jak抑制剂及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20221125 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) |